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 Cells maintain exquisite control over gene expression in the struggle to preserve 
homeostasis. While some genes remain constitutively active to function in energy 
production or provide mechanical support, other batteries of genes respond only in the 
context of specific stresses, and must be silenced when homeostasis is achieved. 
Numerous transcription factors have been identified as responders to stress, whose gene 
targets aid in maintaining homeostasis. An additional layer of regulation over the 
relatively static genetic code involves chemical modifications of histones and DNA, 
particularly in or near gene promoters. Recent advances in the understanding of such 
epigenetic changes show that methylation at the 5-carbon position of cytosines 
neighboring guanosines (CpG) is an important player in the regulation of mammalian 
genes and chromatin architecture. Moreover, methyl groups can be further modified by 
a reaction catalyzed by Ten-Eleven Translocation (TET) 5-methylcytosine dioxygenases, 
whose products were shown to be intermediates in DNA demethylation as well as stable, 
final products that may have functional relevance. DNA methylation has therefore 
become increasingly viewed as a dynamic process, yet the proteins regulating epigenetic 
marks and gene expression remain poorly-understood. Because changes in CpG 
methylation underlie numerous threats to health, including cancer and neurodegenerative 
diseases, these proteins are potential targets in developing biomarkers and in drug 
development.   
 This dissertation explores the role of TET1 in response to cellular stress. Toward 
this end, an in vitro approach was taken in order to manipulate TET1 levels and measure 
the response to toxicant-induced stress. Two major roles for TET1 were elucidated. First, 
reactive oxygen species generated by exposure to the benzene metabolite hydroquinone 
(HQ) led to genome-wide and gene-specific CpG demethylation in a TET1-dependent 
manner. Moreover, cytoprotective genes induced by HQ were dependent on TET1, 
suggesting the protein is involved in transcriptional responses to stress. Secondly, a role 
for TET1 in the response to DNA damage was uncovered and found to be unrelated to 
catalytic activity, indicating a novel, non-enzymatic role for TET1. Taken together, these 
data suggest that TET1 represents a heretofore unappreciated interface between the 
environment and the cellular response to stress. 
 
 
 The findings presented are used to support the underlying hypothesis that TET1 is 
involved in mediating responses to stresses which would be harmful to the genome if left 
unconstrained. The idea that TET1 plays a protective role linked to disease is 
strengthened by reports of nearly uniformly low levels of TET proteins and their products 
in cancers.  Highlighting the role of TET1 as a critical protector of the genome may serve 
as a foundation upon which a better understanding of the role of DNA methylation in 
disease may be built. Ultimately, unraveling the protein’s functions – both enzymatic and 
non-enzymatic - will lead to improved prevention and treatment strategies in diseases 
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1.1   The role of DNA methylation in the cell 
1.1.1   DNA methylation and its machinery 
 Mammalian cells have the capability of regulating genes by chemically modifying 
DNA in a way that is stable and heritable, yet without changing the sequence of bases. 
Greater than 50% of human genes contain regions of the genome that have a high density 
of cytosines neighboring guanines (CpG). Cytosines are frequently methylated at the 5-
position of the carbon ring, and are susceptible to deamination. This vulnerability over 
the course of mammalian evolution led to CpG clusters within gene promoters, most of 
which are unmethylated (38). These CpG Islands are located in gene promoters and are 
capable of being methylated as a means of controlling gene expression. DNA methylation 
is a covalent modification catalyzed by DNA methyltransferases (DNMTs).  
 DNMT3A and DNMT3B, known as the “de novo methyltransferases” establish 
new methylation marks on cytosines, which are thought to be critical in silencing the 
expression of retrotransposons and satellite repeat sequences, as well as controlling the 
dosage of genes via imprinting of one allele. DNMT1, known as the “maintenance 
methyltransferase,” recognizes hemimethylated DNA and ensures that methylation 
patterns are copied during DNA replication. Interestingly, DNMT1 interacts with 
proliferating cell nuclear antigen (PCNA), allowing it to target proliferating foci during 
DNA synthesis. DNMT3L is homologous to DNMT3A and DNMT3B, but does not have 
catalytic activity (39). The gene is highly expressed in germ cells, and is involved in 
regulating DNMT3A and DNMT3B activity. The importance of DNA methylation was 
highlighted through the use of knockout mice. Dnmt3a knockout mice developed to term, 
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but were not viable after 3-4 weeks. Dnmt3b knockout attempts were not successful, as it 
was embryonic lethal at E14.5-18.5 (39). These models indicated that de novo DNA 
methylation is essential in mammalian development and growth. Dnmt1 knockout mice 
die early in embryogenesis. However embryonic stem cells derived from the embryos 
have been cultured, but lack a significant amount of DNA methylation and die during 
induced differentiation (38, 39). Dnmt3L –deficient mice have profound genome-wide 
demethylation and display developmental arrest at E8.5 (39). The profound effects of 
losing these enzymes are indicative of their importance in development. 
 
1.1.2   Roles of DNA methylation in mammalian cells 
 CpG methylation, particularly in gene promoters, is generally associated with 
gene silencing. The methyl groups on the 5-position of the cytosine ring project into the 
major groove of DNA. While it is thought that this bulky projection may be sufficient to 
inhibit transcription, it has been shown that methyl groups prevent transcription factors 
from binding (2, 40). In fact, methylation patterns may act as a code exploiting the 
differential sensitivity of some transcription factors to bind methylated DNA. Specific 
methyl-DNA binding proteins are also known to interact with histone deacetylases 
(HDACs), which participate in changing the chromatin structure from permissive 
euchromatin to restrictive heterochromatin by removing transcription-promoting 
acetylation marks from histones (38). The interaction between methyl-DNA binding 
proteins and histones illustrates the close mechanistic relationship between DNA 
methylation and chromatin marks. Lysines and arginines in histones are methylated and 
acetylated. Depending on the location and makeup of the local marks, the modifications 
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can greatly influence the histone structure, making the chromatin more or less accessible 
to transcriptional machinery (40).   
 Epigenetic modifications are a major determinant of tissue identity and 
differentiation, as the genetic code remains the same, yet differentiated cells must silence 
genes involved in pluripotency and genes of other tissue types to maintain their identity. 
DNA methylation participates in mammalian development, and the properly established 
patterning is crucial for proper functioning of the adult (2,41). An extreme example of 
DNA methylation occurs when the parental genome of a fertilized egg undergoes rapid 
global demethylation. This process is an active demethylation, known to be due to TET3 
(discussed below). The maternal genome is demethylated in a passive manner, by a 
decreases in expression and activity of DNMTs (40). DNA methylation patterns, quickly 
reestablished by DNMT enzymes, are essential for the development of the organism (41). 
As embryonic programs are set toward a specific lineage, de novo methylation by 
DNMT3A and DNMT3B. Embryonic stem cells lacking DNMTs are incapable of 
differentiation (39). Pluripotency-associated promoters such as Pou5f1 (Oct4) and Nanog 
are silenced by methylation upon differentiation, resulting in the inability to 
dedifferentiate (42). A well-known example of the involvement of DNA methylation is 
neural progenitor cell (NPC) differentiation. NPCs, capable of differentiating into 
neurons, astrocytes, and oligodendrocytes, restrict their ability to become astrocytes as 
they differentiate toward a neuronal fate. A CpG site in the STAT-binding element in the 
promoter of numerous astrocytic genes is methylated, and prevents the transcription of 
astrocytic genes (43). This progressive restriction of gene expression is thought to 
control, in part, differentiation of stem cells into more differentiated lineages.   
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 An additional function of DNA methylation is the silencing of retrotransposable 
elements, some of which make up approximately 19% of the genome (26). For example, 
Long Interspersed Nuclear Element 1 (LINE-1), a retrotransposon encoding an RNA 
binding protein and an endonuclease with reverse transcriptase activity, makes copies of 
the DNA via an RNA intermediate, which is then inserted into the host genome at a new 
site. Left unchecked, LINE-1 would quickly overtake the genome and directed, orderly 
transcription would be inhibited, if possible at all. LINE-1 is heavily methylated to 
prevent such an attack on the genome. Methyl-CpG binding protein 2 (MeCP2) is known 
to help repress LINE-1 activity (23). Interestingly, recent evidence shows that new 
experiences and exercise cause increases in LINE-1 retrotransposition in rat neurons. It is 




1.1.3   DNA methylation and disease 
 
 Altered DNA methylation has long been recognized as a distinguishing feature in 
disease (2). In cancers, DNA is typically globally hypomethylated, yet hypermethylated 
in CpG islands. Non-cancer cells typically have very few methylated CpG island , though 
CpG island methylation occurs in X-chromosome inactivation and imprinting and 
increases with age. Tumors suppressor genes are often methylated in human cancers, 




 A causative role for methylation in carcinogenesis is supported by the fact that 
reducing DNA methylation in ApcMin/+ 
 
mice led to fewer intestinal tumors. In addition, 
methylation of tumor suppressor genes often occurs early in tumorigenesis (39), and has 
been shown to act as the “second hit” in Knudson’s Two-Hit Hypothesis, where one 
tumor suppressor allele is lost by mutation and the other is methylated (40). Rb, APC,  
and BRCA1 are examples of commonly methylated tumor suppressor genes involved in 
cell-cycle regulation, Wnt signaling, and DNA repair, respectively. Cytosine analogue 
drugs inhibiting DNA methylation, including Decitabine and Zebularine, are currently in 
use as a form of chemotherapy (45,46) . The idea behind the therapy involves relieving 
the repression of tumor suppressor genes that will halt cell division or initiate apoptosis. 
A potential benefit over targeting specific oncogenes could be that tumors are 
heterogeneous and evolve to evade inhibition of oncogenic drivers. By combining 
targeted therapies along with demethylating agents, it is hoped that tumor cells will 
become sensitive to activated tumor suppressor genes they have evolved to silence (45).  
 
Neurologic Diseases and Syndromes 
 
 Fragile X Syndrome is among the most common forms of inherited syndromes 
involving cognitive impairement and learning disabilities. The syndrome is caused 
mainly by a massive expansion of C-G-G triplet repeats found in the 5’ UTR of the 
FMR1 gene (47). Patients with Fragile X Syndrome have hypermethylation of the C-G-G 
Fragile X Syndrome 
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repeats, leading to silencing of the FMR1 gene (47). The gene product is an RNA-binding 
protein that translocates between the cytoplasm and nucleus. It is thought that the absence 
of the FMRP protein inhibits protein synthesis in dendrites, leading to massive cognitive 
deficits (48).   
 
 Alzheimer’s disease (AD) is a progressive neuropsychiatric illness characterized 
by brain atrophy, cognitive impairment, inflammation, and emotional disturbance. The 
disease commonly also causes memory loss, apathy, depression, and irritability. Both 
hyper- and hypomethylation of genes have been observed in AD. For example, 
hypomethylation of COX-2 promoter has been observed in a study involving tissues from 
10 diseased and 10 non-diseased frontal cortex samples (49). Hypermethylation of BDNF 
was observed in the same study, which was accompanied by a significant decrease in 
mRNA. Perhaps most significantly, CpG methylation of the NF-k B promoter was found 
to be hypomethylated in AD brain. The investigators noted an increase in p50 and p65 
expression as well, suggesting that the neuroinflammation observed in AD patients could 
result from hypomethylation of the NF-• B promoter (49). Conflicting reports of global 
DNA methylation have yet to be resolved; both global hypermethylation and 
hypomethylation have been reported in AD samples. Using an ELISA-based approach, 
Rao et al. observed an increase in global DNA methylation along with global histone H3 
acetylation (49). However, Chouliaras et al. observed a global decrease in both 
methylation and hydroxymethylation in the hippocampus of Alzheimer’s disease (50). 
Both groups measured DNA methylation using antibody-based approaches, but it is not 
Alzheimer’s Disease  
clear which cell types were represented in each sample. Because the brain contains 
numerous cell types in close proximity to one other, it can be difficult to tell whether 
changes in methylation are due to changes in methylation of neurons, or whether the 
death of neurons and the proliferation of astrocytes contributed to the changing 







 - and a-ketoglutarate-dependent dioxygenases  
1.2.1  Background and mechanisms  
  Members of the family of Fe
2+
 - and a-ketoglutarate (aKG) -dependent 
dioxygenases catalyze numerous oxidation reactions involving a wide range of substrates, 
including proteins, fatty acids, amino acids, and nucleic acids. The large number of 
substrates corresponds to the wide-range of cellular processes to which these 
dioxygenases contribute. They are distinguished from the well-known family of 
cytochrome P450 monooxygenases by their incorporation of both oxygen atoms in the 
dioxygen molecule into organic products (61). While P450 enzymes rely on reductants 
such as NADPH2 to reduce an oxygen atom to water, aKG dioxygenases use a-
ketoglutarate as a substrate for oxidation in addition to the principal substrate. 
Additionally, cytochrome P450 monooxygenases contain heme-bound iron at their 
catalytic sites, while aKG-dependent dioxygenases directly bind an Fe
2+
 via histidine, 
aspartate/glutamate, and histidine coordination, referred to as a HXD/E…H motif (62) . 
aKG dioxygenases contain a double stranded B-helix (DSHB) fold made up of eight B-
strands known to contain cofactor -coordinating pockets. a-helices located n-terminal to 
the B-strands are capable of coordinating a zinc ion, which may play a role in DNA 
binding (61).  
 aKG dioxygenase active sites are located in the DSBH core, where Fe
2+ 
, aKG, 
and substrate bind, followed by dioxygen. It is thought that the ordered binding 
minimizes the time substrate is kept in close proximity to potentially reactive oxidizing 
species, thus protecting substrate from damage (61). An Fe
2+ 
-derived electron generates 
a superoxide radical that attacks the carbon-2 position of aKG producing a covalent bond 
between the resulting Fe
4+ 
center and aKG. The aKG intermediate is decarboxylated, 
resulting in succinate and CO2, while leaving an Fe
4+ 
-oxo intermediate in the active site. 
This remaining intermediate becomes reduced via substrate-derived hydrogen atom, 
leaving a substrate-radical. The carbon of the substrate is oxidized by the addition of an 
oxygen atom, yielding a hydroxyl group on substrate (61). This final oxidation step, in 
the presence of ascorbate, regenerates the Fe
2+ 
in the active site. It is thought that all aKG 
dioxygenases follow this general mechanism, and most identified members of this family 
of enzymes add a hydroxyl group to the non-aKG substrate. Interestingly, aKG 
dioxygenases are emerging as a family of proteins capable of sensing and responding to 
cellular microenvironmental conditions, suggesting they may play a critical role in 
diseases such as cancer and in maintaining homeostasis in the face of various stresses. 
 
 
1.2.2  Prolyl hydroxylases as environmental sensors  
 The prolyl hydroxylases are by far the most well-known Fe
2+
 and aKG-dependent 
dioxygenases whose activities respond dramatically to changes in the cellular 
microenvironment and therefore serve as the prototypical interface between the 
microenvironment and programmed response to stress. It was recognized long ago that 
the 4-hydroxyproline necessary for collagen function in tissues was formed by collagen 
prolyl-4-hydroxylases, and deficiency in these proteins or ascorbate, leads to scurvy. 
Other members of the same family of Fe
2+
 and aKG-dependent dioxygenases were later 
found to be involved in the sensing of oxygen availability (63). Transcriptional regulation 
of genes involved in the cellular response to hypoxia was determined to be controlled by 
the transcription factor Hypoxia-inducible factor (HIF). Proteomic analysis revealed that 
two proline residues of HIF-a became hydroxylated under normoxia, and it was known 
that HIF-a underwent ubiquitin-mediated proteasomal degradation. Under conditions of 
hypoxia, the HIF-a subunit (but not HIF-B) is liberated from proteasomal degradation 
pathways and translocates to the nucleus to activate a battery of more than 60 genes 
involved in overcoming hypoxia, including vascular endothelial growth factor (VEGF), 
erythropoietin, and glucose transporters (64). The discovery that two proline residues 
were critical to the responsiveness of HIF-a and the later finding that HIF-a 
hydroxylation was dependent on Fe and aKG implicated Fe
2+ 
and aKG-dependent 
dioxygenases in the hydroxylation of HIF-a and the overall cellular response to hypoxia. 
The genes responsible for hydroxylating HIF-a were found to be the prolyl hydroxylases 
PHD1-3 and a HIF asparaginyl hydroxylase, FIH-1  (63).  
 Numerous cancers have shown the ability to circumvent hypoxia-mediated 
toxicity and, not surprisingly, these cancer often display high levels of HIF proteins, 
which confer resistance to overgrowth of the tumor blood supply by signaling growth of 
new vasculature. HIF proteins also support the invasion of cancer cells into adjacent 
tissues by increasing the expression of matrix metalloproteinase 2 (64). HIF proteins have 
therefore become targets of anticancer therapeutic agents, and have become an important 
player in our understanding of cancer biology. Interestingly, Isocitrate dehydrogenase -1 
and -2 (IDH1,2) mutations (R132H) result in the formation of 2-hydroxyglutarate (2HG) 
rather than a-ketoglutarate, which reportedly inhibit numerous aKG-dependent 
dioxygenases. However, enantiomer-specific changes in collagen prolyl 4-hydroxylase 
activity have been observed in cells with mutant IDH1 or IDH2. R-2HG was reported to 
increase EglN1 and EglN2 activity, thereby decreasing HIF levels, while S-2HG had no 
effect (65). This raises the possibility that IDH status may confer differential sensitivity 
to specific therapies via the production of cofactors that alter aKG-dioxygenase activity. 
1.3 Ten Eleven Translocation 5-methylcytosine dioxygenases  
1.3.1 The discovery of TET proteins  
 Ten Eleven Translocation (TET) proteins are named for the ten-eleven 
translocation (t(10;11)(q22;q23)) observed in rare acute myeloid and lymphocytic 
leukemia (7). The product of the translocation is a fusion of the mixed-lineage leukemia 
(MLL1) gene, on chromosome 10, with the TET1 gene on chromosome 11. Following the 
discovery of the TET1 gene, three proteins have been described: TET1, TET2, and TET3. 
It was predicted that the proteins may affect DNA by the known DNA modifying activity 
of the J-binding protein 1 (JBP1) protein from Trypanosoma brucei, the trypanosome 
causing human African Sleeping Sickness (51). These organisms contain a modified 
thymine molecule known as “base J,” a glucosylated hydroxymethyluracil. JBP1 and 
JBP2 are capable of oxidizing the methyl group of thymine to form hydroxymethyluracil 
and, based on the amino acid sequence, the protein was identified as a homologue to the 
metazoan TET protein (51). A gene resembling the TET-JBP family fused with a gene 
containing a CXXC DNA-binding domain and led to the three members found in 
metazoans. Both TET proteins and the JBP proteins are divalent iron- and a-
ketoglutarate-dependent dioxygenases, though the target of the TET proteins is 5mC 
rather than thymidine (7).  
 
 
1.3.2 Functional domains of TET proteins  
 TET1 and TET3 contain an amino terminal CXXC domain, and all three TET 
genes contain a carboxy terminal catalytic domain. The TET proteins contain a cysteine-
rich domain toward the carboxy terminus, which the JBP members lack. Interestingly, the 
ancestral TET gene underwent a triplication event, leading to three similar TET genes. 
TET2, however, lost its CXXC domain in an apparent inversion (51). The exon is now a 
separate gene transcribed in the opposite direction, known as IDAX. IDAX has been 
shown to recruit TET2 to the nucleus, targeting it for caspase-mediated destruction 
following enzymatic activity. The remaining CXXC domains are not necessary for 
enzymatic activity of TET1 or TET3, and the domains may not even bind DNA with the 
same affinity as the similar CXXC domains found in DNMT proteins (52). It is still 
unclear how TET1 and TET3 are regulated, and whether specific domains – other than 
the catalytic core – have any function.  
            The catalytic domains of TET proteins are typical divalent iron- and α-ketoglutarate- 
dependent dioxygenases, which involves a His-Xaa-Asp/Glu motif. A His residue, C-
terminal to the catalytic domain, coordinates divalent iron, and an Arg residue 
coordinates the a-ketoglutarate (51).  
 
 
1.3.3 Demethylation of 5mC via oxidation  
 Maintenance of DNA methylation involves DNMT1, which recognizes 
hemimethylated CpGs (39). 5mC is hydroxylated by TET proteins to 5-
hydroxymethylcytosine (5hmC) and, because DNMT1 has greatly decreased affinity for 
5hmC, methylation of the newly synthesized CpG does not occur. This possibility of 
passive demethylation is similar to the chemical inhibition of DNA methylation by 5-aza-
2’-deoxycytidine (52).  
 
 
1.3.4 Active demethylation of 5mC via oxidation  
 TET enzymes have been shown to yield 5-formylcytosine (5fC) and 5-
carboxycytosine (5caC). In this proposed mechanism, 5mC is oxidized to become 5caC 
through iterative TET activity. 5caC could be excised by thymidine DNA glycosylase 
(TDG) and replaced by cytosine. While a plausible mechanism, the extremely low 
abundance of 5caC found in cells known to undergo active demethylation makes the 
mechanism less likely or perhaps a minor one.  
 An alternative mechanism involves the deamination of TET-derived 5hmC, 
forming 5-hydroxymethyluracil (5hmU). Base excision repair (BER) enzymes could then 
replace 5hmU with unmethylated cytosine (7). One caveat in this proposed pathway is the 
finding that deaminases (e.g. AID, APOBEC1-2) have greater affinity for single-stranded 
DNA than double stranded DNA. It is reported, however, that AID can alter the sub-
cellular localization of TET proteins from the cytoplasm to the nucleus (53), though the 
role of AID in the demethylation pathway would then be an indirect one.  
 Evidence suggests that the oxidation-deamination pathway may be a significant 
contributor to active DNA demethylation. Guo et al. demonstrated that both 
overexpression and knockdown of deaminases led to decreases and increases in 5hmC 
levels, respectively, in TET1-overexpressing cells, supporting deaminase activity in the 
deamination of 5hmC (7). Additionally, small molecule inhibitors of BER led to a 
decrease in demethylated 5mC, further supporting the pathway (7). 
 
II.   The benzene metabolite hydroquinone leads to active cytosine demethylation 
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2.1  ABSTRACT 
 DNA methylation regulates gene expression throughout development and in a 
wide range of pathologies such as cancer and neurological disorders. Pathways 
controlling the dynamic levels and targets of methylation are known to be disrupted by 
environmental and pharmaceutical chemicals and are therefore of great interest in both 
prevention and clinical contexts. Benzene and its metabolite hydroquinone have been 
shown to lead to decreased levels of DNA methylation, although the mechanism is not 
known. This study employs a cell culture model to investigate the mechanism of 
hydroquinone-mediated changes in DNA methylation. Exposures that do not affect 
HEK293 cell viability led to genomic and methylated reporter DNA demethylation. 
Hydroquinone caused reactivation of a methylated reporter plasmid that was prevented 
by the addition of N-acetylcysteine. Hydroquinone also caused an increase in Ten Eleven 
Translocation 1 activity and global levels of 5-hydroxymethylcytosine. 5-
Hydroxymethylcytosine was found enriched at LINE-1 prior to a decrease in both 5-
hydroxymethylcytosine and 5-methylcytosine. Ten Eleven Translocation-1 knockdown 
decreased 5-hydroxymethylcytosine formation following hydroquinone exposure as well 
as the induction of glutamate-cysteine ligase catalytic subunit and 14-3-3 . Finally, Ten 
Eleven Translocation 1 knockdown decreased the percentage of cells accumulating in 
G2+M following hydroquinone exposure, indicating that it may have a role in cell cycle 
changes in response to toxicants. This work demonstrates that hydroquinone exposure 
leads to active and functional DNA demethylation in HEK293 cells in a mechanism 






2.2   INTRODUCTION 
 DNA methylation is dynamic, and the mechanisms involved in methylation and 
demethylation represent an interface between the environment and gene expression (1). 
Changes in DNA methylation have been implicated in a wide range of pathologies 
including cancer (2), neurodevelopmental disorders (3), and chronic inflammation (4). 
Efforts to understand mechanisms involved in DNA methylation and demethylation 
therefore have enormous translational potential. DNA methylation is established and 
maintained by the family of DNA methyltransferases (DNMTs),3 although mechanisms 
underlying demethylation have been more difficult to elucidate. Whereas Arabidopsis 
DNA glycosylases DME and ROS1 participate in exchanging methylcytosines with 
cytosines, no analogous pathway has been discovered in mammalian cells (5). A number 
of chemicals, such as 5-aza-2-deoxycytidine, decrease DNA methylation passively by 
inhibiting maintenance methylation as DNA is synthesized (6). However, this mechanism 
depends on cell division and may not explain active demethylation in post-mitotic cells 
such as neurons (7) and in the early stages of embryogenesis.  
 Pharmaceutical, industrial, and environmental chemicals have also been shown to 
decrease DNA methylation, but the mechanisms are unclear (8, 9). Several chemicals 
have been shown to have a passive effect on methylation by modifying DNMTactivity 
(10, 11).An interesting target that could explain active demethylation involves the Ten 
Eleven Translocation (TET) family of Fe  and  -ketoglutarate-dependent 5mC 
dioxygenases (12, 13). In a mechanism proposed by Guo et al., TET proteins catalyze the 
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oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), followed by 
deamination to 5-hydroxymethyluracil by cytidine deaminases. Subsequent base excision 
repair machinery would then replace 5-hydroxymethyluracil with unmethylated cytosine 
(14).  
 In this study, we focused on changes in DNA methylation by the benzene 
metabolite hydroquinone (HQ). Benzene is a ubiquitous environmental toxicant found in 
petroleum products and cigarette smoke (15) that has been associated with aplastic 
anemia and acute myelogenous leukemia (16).HQis one of the most abundant metabolites 
of benzene (17, 18) and has been shown to increase levels of reactive oxygen species 
(ROS) (19, 20), induce mitotic arrest (21), and promote apoptosis (20). Although benzene 
and benzene metabolite exposures have also been shown to be associated with loss of 
genomic methylation (9, 22), no mechanisms have been described to explain the observed 
decreases. The current study investigates a mechanism of DNA demethylation induced by 
exposure to HQ in a cell culture model, demonstrating that HQ mediates DNA 











2.3  RESULTS 
Low Concentrations of Hydroquinone Decrease DNA Methylation  
 The MTT assay was used to determine concentrations of HQ which did not affect 
viability of HEK293 cells. Significant changes in MTT reduction were observed 
following exposure for 24 h to concentrations of 100µM and higher (Fig. 1A). 
Preincubation of cells with buthionine sulfoximine, an inhibitor of glutathione synthesis, 
increased the sensitivity of cells to HQ, indicating the involvement of glutathione and that 
toxicity is mediated in part by ROS. 8-oxo-dG was also measured by immunodotblotting 
genomic DNA. Significant increases in 8-oxo-dG staining were observed at 100µM HQ 
and 500µM H2O2
 
 (Fig. 1B) but not at 60µM HQ, although a 40% decrease in genomic 
5mC was observed (Fig. 1C). Increases in ROS were observed as early at 4 hours 
following exposure to 60µM HQ and levels of ROS were lower in cells incubated with 











Figure 1: Effects of hydroquinone on viability and DNA methylation in HEK293 cells. 
A, MTT assay results following HQ exposure for 24 hours are shown. Cells were 
incubated for 14 hours with 0.5 mM buthionine sulfoximine or an equivalent volume of 
vehicle prior to HQ exposure. B, cells were exposed to indicated concentrations of HQ 
for 20 hours or H2O2
 
 for 0.5 hours . C, 250 ng of genomic DNA was then denatured, 
vacuum-baked to a nitrocellulose membrane, and probed with antibody against 8-oxo-dG 
or 5mC and normalized to methylene blue staining. D, ROS was measured by DCF-DA 

















Hydroquinone-Mediated Decreases in Methylation are Active and Functional and 
Involve Reactive Oxygen Species 
 A possible mechanism involved in decreased methylation in the absence of 
oxidative DNA damage could involve inhibition of DNMT1, as many of the cells would 
have passed through S phase within 24 hours. A reporter assay was established to 
examine this possibility. The Nit-GFP plasmid is replication-incompetent and would 
therefore be less likely to undergo demethylation passively (16). Moreover, the 
functionality of CpG methylation can be ascertained by measuring GFP expression. 
Nearly complete repression of GFP was observed in cells transfected with the reporter 
plasmid that was methylated with CpG methyltransferase and S-adenosylmethionine (Fig. 
2.A).  A 24 hour exposure to HQ was sufficient to reactivate the methylated reporter. A 2- 
and 3-fold increase in GFP+ cells was observed in cells transfected with the reporter and 
exposed to 60- and 100µM HQ, respectively (Fig. 2B). Interestingly, the increase in 
GFP+ cells was prevented by co-incubating 60µM HQ-exposed cells with NAC, 
suggesting that ROS was involved in reactivation of the methylated plasmid by HQ (Fig. 
2C). Bisulfite sequencing of the promoter confirmed both pre-transfection methylation of 
the plasmid promoter and an increase in unmethylated CpGs following 24 hour exposure 








Figure 2:  HQ causes ROS-dependent active and functional DNA methylation. A, 
Histogram of GFP intensity in unmethylated (dotted curve) and methylated reporter 
plasmid (solid curve) relative to untransfected cells (filled curve). B, Dose-response of 
plasmid reactivation in cells transfected with methylated reporter plasmid and exposed to 
HQ for 24 hours. C, Reactivation of methylated reporter plasmid by 60 µM HQ alone or 
in combination with NAC is shown. GFP+ cells were quantified by flow cytometry. n = 
4, Values are mean  ± S.E. (error bars). D, Bisulfite sequencing of methylated 
methylation-sensitive reporter plasmid promoter in control and HQ-exposed HEK293 

















Hydroquinone Increases Genomic 5-Hydroxymethylcytosine Levels  
 Due to the recent interest in active demethylation pathways involving TET 
proteins, immunodotblotting was used to measure 5hmC in genomic HEK293 DNA 
following HQ exposure. In order to establish a method to measure genomic 5hmC with 
specificity, genomic DNA from untransfected or TET1 catalytic domain (TET1cd) 
overexpressing HEK293 cells was immobilized onto a nitrocellulose membrane and 
probed using an antibody against 5hmC that was pre-incubated with 2µg/mL 5hmC or 
5mC. Pre-incubation of the antibody with 5hmC, but not 5mC, diminished the signal 
(Fig. 3A), indicating specificity for 5hmC. To normalize 5hmC staining, an antibody 
against single-stranded DNA (ssDNA) was used. To avoid overloading membranes, 
increasing amounts of genomic DNA from HEK293 cells was immunoblotted using three 
concentrations of antibody (Fig. 3B). Because more than 640ng of DNA was out of the 
linear range of detection, immunodotblotting was accomplished using less than 500ng of 
genomic DNA. Noting a decrease in 5mC following 24 hours of HQ exposure, a time 
course of 5hmC was conducted to examine the potential for 5hmC as a demethylation 
intermediate. 5hmC levels increased at 8 and 12 hours following HQ exposure, but were 
not significantly higher at 24 hours (Fig. 3D). A dose response was also observed for 
5hmC levels 18 hours following exposure to HQ and menadione (Fig. 3E), which is 







Figure 3: Hydroquinone increases genomic 5hmC levels. A, Antibody specificity was 
confirmed by immunodotblot of 500ng HEK293 genomic DNA with and without 
TET1cd overexpression. Anti-5hmC antibody was incubated with 2µg/mL 5hmC or 5mC 
for 2 hours at room temperature and used to probe DNA. Anti-ssDNA antibody was used 
to normalize to total DNA. IR dye-conjugated IgG antibodies (mouse: 600, rabbit: 800) 
were used for simultaneous visualization by Licor Odyssey Imager.  B, Varying amounts 
of HEK293 DNA were loaded onto nitrocellulose membrane and probed with 3 
concentrations of ms anti-ssDNA antibody to confirm DNA amounts used in 
immunodotblotting were within a linear range for 5hmC normalization. Antibody signal 
was quantified and plotted in C.  D, 5hmC in HEK293 cells following 8-, 12-, and 24-
hour exposures to HQ measured using immunodotblotting. E, Immunodotblot showing 
dose-response for 5hmC following various concentrations of hydroquinone or menadione 
after 18 hours. Results were quantified and are represented in F. Values are mean_S.E. 











                            




























Hydroquinone-Induced 5-Hydroxymethylcytosine Formation is Dependent on TET1 
5mC Dioxygenase 
 TET activity was higher in HQ-exposed HEK293 cells to levels similar in cells 
overexpressing TET1 catalytic domain (Fig. 4A). Although there are three distinct family 
members of TET proteins, we found that siRNA-mediated knockdown of TET1 led to an 
approximate 75% decrease in both Tet1 mRNA (Fig. 4B) and total TET activity (Fig. 
4C), suggesting that TET1 is the major TET protein contributing to 5hmC in HEK293 
cells. siRNA against Tet1 did not affect Tet2 or Tet3 mRNA levels (Fig. 4B), but 
completely abrogated HQ-induced increases in 5hmC (Fig. 4D), indicating that the 














Figure 4: Hydroquinone increases 5hmC through TET1.A, 5hmC formed from nuclear 
extracts of HEK293 cells exposed to 0 or 60 µM HQ or overexpressing (OE) FLAG-
tagged Tet1 catalytic domain. B, Tet1, 2, and 3 mRNA measured by qRT-PCR following 
transfection with Tet1-targeted or control siRNA. Tet expression was normalized to 
GAPDH. C, 5hmC formed from HEK293 nuclear extracts following control or Tet1 
knockdown. D, immunodotblotting of genomic DNA from cells exposed to 60µM HQ 
following control or Tet1-targeted knockdown. Values are mean±S.E. (error bars), n=3. 
* significance compared with control by t test (A, B, and C) and one-way ANOVA and 

















Hydroquinone Exposure Leads to Increased Nuclear TET1Levels in HEK293 Cells 
 Because TET1 loss-of-function abrogated HQ-induced increases in 5hmC, efforts 
were directed toward understanding how HQ alters TET1 activity. No increase in TET1 
mRNA was observed following exposure to HQ (Fig. 5A), suggesting HQ may alter 
TET1 post-transcriptionally. To determine the relationship between TET1 protein and 
activity, levels of TET1 protein in nuclei were measured by Western blotting. A 75% 
increase was observed in TET1 protein following exposure to 60µM HQ (Fig. 5B and C). 
A 60% decrease in the band was observed in cells transfected with TET1 siRNA, thereby 
confirming the identity of the band as TET1 (Fig. 5, D and E).  
 To further test the possibility that HQ affects TET1 post-transcriptionally, flag-
tagged TET1 driven by CMV promoter was overexpressed and measured by Western blot 
following HQ exposure. An increase in both cytoplasmic and nuclear TET1 protein (Fig. 
5F and G) was observed in cells exposed to HQ. The increase in protein driven by an 
alternate promoter supports the idea that HQ affects TET1 levels in a post-transcriptional 
manner.  
 Because HQ exposure led to functional demethylation, 5hmC formation, and an 
increase in total Tet activity and nuclear TET1 levels, it was reasoned that overexpression 
of deaminase proteins should enhance reactivation of the methylated GFP reporter. 
Indeed, overexpression of V5-tagged human Apobec 2 (AP2) increased the GFP+ 
population approximately 2-fold following 60 µM HQ exposure (Fig. 5H), suggesting 
that HQ-mediated DNA demethylation occurs through recently proposed oxidation-





Figure 5: Effects of hydroquinone on nuclear TET1 levels. A, Tet1 mRNA from 
HEK293 cells transfected with control or Tet1-targeted siRNA was measured by qRT-
PCR with and without 60µM HQ exposure for 24 hours. B, Western blot of nuclear 
lysates from HEK293 cells exposed to 0 or 60µM HQ for 24 hours. Tata-binding protein 
(TBP) was used as a loading control. Quantification of TET1/TBP is shown in C. D, 
Western blot of TET1 levels in whole cell lysates from HEK293 cells transfected with 
control or Tet1-targeted siRNA. Quantification of TET1 levels is shown in E.  F, 
reactivation of methylation-sensitive reporter by HQ alone or with overexpression of 
human V5-tagged cytidine deaminase AP2. GFP+ cells were quantified by flow 
cytometry. Western blot of cytoplasmic (G) and nuclear (H) lysates from HEK293 cells 
transfected with FLAG-tagged TET1cd driven by CMV promoter and exposed to 0 or 
60µM HQ. GAPDH and TBP were used as loading controls for cytoplasmic and nuclear 
lysates, respectively. Values are mean_S.E. (error bars), n_3. *, significance compared 





































TET1 Mediates Gene Expression Induced by Hydroquinone 
 The results from the experiments involving the reporter plasmid suggest that HQ 
increases 5hmC and the involvement of TET1 in the mechanism. Genomic regions 
enriched for 5hmC and 5mC were isolated by immunoprecipitation and probed using 
qPCR. A 3-fold enrichment of the open reading frame 2 (ORF2) of the retrotransposon 
LINE-1 was observed in cells exposed to 60 µM HQ for 12 hours without a significant 
change in 5mC (Fig. 6A). At 24 hours, the enrichment of 5mC and 5hmC was decreased 
by 10- and 2-fold, respectively. The data support a role for HQ-induced 5hmC formation 
prior to demethylation, consistent with Tet-mediated oxidation-deamination 
demethylation. In addition, the effects of HQ on DNA methylation are widespread, 
considering the frequency of LINE-1 in the human genome (26). 
 Attention was then focused on 5hmC formation at promoters of genes that are 
known to be induced by HQ. GCLC is a component of the glutamate-cysteine ligase 
protein, the rate-limiting enzyme in glutathione synthesis. ROS disrupts Keap1-
dependent sequestration of the transcription factor Nrf2, resulting in the transcription of 
numerous antioxidant response element-containing genes, including GCLC. 5hmC was 
enriched approximately 12-fold at the promoter of GCLC following a 12 hour exposure 
to HQ, whereas 5mC levels were significantly lower at 12 and 24 hours (Fig. 6B). While 
GCLC mRNA was induced by 2.5-fold in response to HQ in HEK293 cells, induction 
was attenuated in cells following siRNA-mediated TET1 knockdown (Fig. 6C). No 
changes in oxidized glutathione were observed following exposure to HQ with or without 
TET1 knockdown (data not shown). 
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 Because previous studies reported accumulation of cells in G2
 Interestingly, 14-3-3  promoter hypermethylation has been reported in numerous 
cancers and correlates strongly with a decrease in expression (31). In addition, 14-3-3  
expression can be increased by exposure to 5-aza-2’-deoxycytidine (32), and its 
overexpression leads to a mitotic arrest in different cell types (29). Similar to studies 
shown to link HQ to cell cycle arrest, HQ caused an increase in cells in G
+M phases of the 
cell cycle after exposure to HQ, the effect of HQ on methylation of the 14-3-3  promoter 
was studied. 14-3-3 is a p53-regulated inhibitor of cdc2-cyclinB1 nuclear translocation 
and is known to be regulated by promoter methylation (27–30). An enrichment of 5hmC 
was observed (Fig. 6D) at the 14-3-3  promoter following a 12 hour exposure to HQ and 
decreased 5mC at 12 and 24 hours. Induction of 14-3-3  expression by HQ was also 
blocked by TET1 knockdown (Fig. 6E). To confirm the role of TET1 in 5hmC formation 
at these promoters, TET1cd was overexpressed and cells were exposed to HQ for 24 
hours. ChIP confirmed an increase in binding at GCLC and 14-3-3  promoters following 
exposure to HQ compared to control (Fig. 6F and G).  
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+M (Fig. 6H). 
Further experiments were directed to examine whether TET1 plays a role in the changes 







Figure 6:  Cytoprotective genes induced by hydroquinone are TET1-dependent. A, 
Genomic DNA was sonicated and immunoprecipitated using antibodies against 5hmC or 
5mC and used as templates for qPCR to measure enrichment of LINE-1 (A), 
GCLCpromoter (B), and  14-3-3  promoter (D) in HEK293 cells following 0-, 12-, and 
24-hour exposure to 60µM HQ.  Ct values were normalized to input values. 
mRNAwas isolated from cells exposed to 60µM HQ for 24 hours following knockdown 
with control siRNA or siRNA targeting Tet1, and qRT-PCR was used to measure levels 
of GCLC (C) and 14-3-3   (E). GAPDH was used as a control in all qRT-PCRs. Values 
are mean ± S.E. (error bars), n = 3. *, significance compared with control by one-way 
ANOVA with Dunnett’s post-test. #, indicate significance compared with siCont + 60µM 
HQ (C and E). F and G, ChIP analysis of  mouse IgG isotype control or FLAG-tagged 
TET1cd bound to GCLC (F) and 14-3-3  (G) promoters  following 24 hour exposure to 0 
or 60µM HQ.  H, Cell cycle profiles of HEK293 cells exposed to 0, 60, 100, or 300µM 
HQ for 24 hours was determined by flow cytometric measurements of DNA content.  
Values are mean ± S.E. (error bars), n = 3. *, significance compared with control by one-
way ANOVA with Dunnett’s post-test. #, indicate significance compared with siCont + 



























































TET1 Mediates Cell Cycle Changes following Hydroquinone Exposure 
 The effects of HQ on the cell cycle were undertaken by measuring DNA content 
with and without HQ exposure in cells transfected with control- or TET1-targeted siRNA 
(Fig 7A-D).  HQ led to an increase in the percentage of cells in G2+M from 15% in 
unexposed cells to 37.5% (Fig. 7D). There was no change in the sub-G0 population by 
HQ exposure. The percentage of cells in G0+G1 phases decreased following HQ 
exposure, but this was likely due to the accumulation of cells in G2+M; TET1 
knockdown did not affect this change in cells in G0+G1 (Fig. 7B). The percentage of 
cells in S phase increased following TET1 knockdown in HQ-exposed cells, from 33 to 
42% (Fig. 7C). TET1 knockdown decreased the number of cells in G2
 The observed increase in TET1-deficient cells in S-phase following HQ exposure 
is measured, by definition, as cells with DNA content between 2n and 4n. A more 
sensitive measure of S-phase quantification, involving labeling DNA-synthesizing cells 
with BrdU, was used to confirm the increase. An increase in BrdU+ cells was observed in 
HQ-exposed cells following TET1 knockdown (Fig. 7E), thereby supporting the 
conclusions made from DNA-content analysis. The data suggest that TET1 may play a 
role in promoting the cellular response to ROS-inducing agents, such as promoting arrest 
of the cell cycle to allow for efficient DNA repair.  
+M following HQ 
exposure to approximately 30% (Fig. 7D). Neither TET1 nor control knockdown had any 





Figure 7: The effect of TET1 on hydroquinone-mediated changes in the cell cycle. A, 
representative cell cycle profiles of HEK293 cells exposed to HQ for 24 h following 
control or Tet1 knockdown are shown. Cells were fixed using methanol:acetone (1:1) and 
stained with propidium iodide. B–D, 10,000 events were collected in each sample 
following control or Tet1 knockdown and exposure to 0 (-) or 60µM HQ (+) and 
percentage of cells in G0+G1 (B), S (C), and G2
 
+M (D) phases were quantified. E, BrdU 
labeled cells following control or TET1 knockdown and exposure to 0 or 60µM HQ. 
Cells were pulsed with BrdU for 6 hours at the end of a 24 hour HQ exposure and BrdU+ 
cells were labeled with anti-BrdU antibody and anti-mouse secondary prior to 
quantification by flow cytometry. Propidium iodide was used as a counterstain to indicate 







































2.4  DISCUSSION 
 Epidemiologic and laboratory data suggest a negative correlation between DNA 
methylation and benzene or hydroquinone exposures (9, 22). We investigated the 
mechanism to account for the decrease by examining the effects of the major benzene 
metabolite, HQ, in HEK293 cells. While the use of an in vitro system as a model for 
changes in tissues is limited by its simplicity, the use of a single cell type avoids the often 
underestimated contribution of the selection of cell types or sub-populations of cells to 
observed changes in DNA methylation. Here, we demonstrate that concentrations of HQ 
that did not affect viability led to decreased DNA methylation in HEK293 cells in a 
mechanism involving ROS.  Using an immunodotblotting technique, we show that 
genome-wide DNA methylation levels are decreased following a 24 hour exposure to 
HQ. The functionality of these decreases in DNA methylation was tested using a GFP 
reporter plasmid, which revealed that HQ-mediated demethylation results in an increase 
in gene expression. Because the plasmid is replication-incompetent (14), it is likely that 
the demethylation is active in nature and does not involve inhibiting the activity of 
DNMTs. HQ is a well known inducer of ROS and oxidative stress through the depletion 
of glutathione (19, 20). The addition of NAC abrogated the reactivation of methylated 
reporter plasmid, suggesting that HQ caused demethylation in a mechanism involving 
ROS. ROS and oxidative stress have been shown to lead to both increases (31) and 
decreases (32, 33) in DNA methylation. Interestingly, the low concentrations of HQ used 
did not significantly increase oxidized glutathione, lipid peroxidation (data not shown), or 
8-oxo-dG formation, indicating that DNA demethylation was induced by relatively low 
levels of ROS that do not result in oxidative stress. This may be particularly relevant in 
39 
 
cells and tissues that are sensitive to changes in redox status or in cases of signaling 
events that may be mediated by ROS. For example, endogenously produced ROS have 
been shown to modulate phosphatase activity at physiologic levels, suggesting that these 
enzymes evolved to be responsive to ROS.  
 Whereas mechanisms explaining DNA demethylation have been largely focused 
on inhibition of the DNMT family of DNA methyltransferases, recent evidence suggests 
a role for the TET family of 5mC dioxygenases in active DNA demethylation. The 
proposed mechanism entails the conversion of 5mC to 5hmC catalyzed by TET1, 
followed by deamination to 5hmU and subsequent base excision repair, resulting in an 
unmethylated cytosine (12–14). Our studies provide support that this mechanism is 
responsible for DNA demethylation in cells exposed to HQ. Immunodotblots of genomic 
DNA from HEK293 cells exposed to 60 or 100 µM HQ reveal significantly higher levels 
of 5hmC than unexposed controls. 5hmC was also enriched at ORF2 of the 
retrotransposon LINE-1 12 hours following HQ exposure, followed by a decrease in both 
5mC and 5hmC at 24 h. As LINE-1 is estimated to comprise 15–19% of human genomic 
DNA (26), these results support the data from immunoblots of genome-wide increases in 
5hmC and also show that the increase in 5hmC is followed by a decrease in genomic 
methylation, which suggests that 5hmC is an intermediate in DNA demethylation in HQ-
exposed cells. The increase and decrease in 5hmC and 5mC, respectively, are also 
associated with gene expression. Enrichment of 5hmC at the promoters of GCLC and 14-
3-3  was associated with increased expression of their mRNAs after exposure to HQ. 
Because 5mC and 5hmC have different binding proteins, suggesting very different 
biological roles in epigenetic regulation, it is not clear whether demethylation is 
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necessary for gene expression or if 5hmC formation alone is sufficient. A possible 
explanation for the rapid decrease in 5mC in GCLC and 14-3-3 but not LINE-1, could 
be that LINE-1 is heavily methylated to approximately 75-90%, and changes in 5mC may 
not be detectable in our immunodotblotting technique until 24 hours post-HQ exposure. 
However, increases in 5hmC which are smaller in magnitude could be detectable in 
LINE-1, as the mark is reportedly relatively low at LINE-1. 
 Previous studies involving chemical- and radiation-induced changes to cytosine 
suggest that direct oxidation of 5mC can lead to 5hmC (34, 35). The lack of 8-oxo-dG 
formation suggests that ROS resulting from 60 µM HQ does not directly oxidize 5mC. 
Instead, exposure to HQ  resulted in an increase in nuclear TET activity. 
Moreover, siRNA-mediated knockdown of TET1 significantly decreased total TET 
activity and prevented HQ-mediated 5hmC formation, highlighting the role of the protein 
in the epigenetic changes following HQ exposure. We also detected higher levels of 
nuclear TET1 by Western blotting with no change in mRNA levels. Although it is 
unclear how protein levels are affected by HQ, TET1 has been shown to form multimers 
via oxidation (12), raising the possibility that its nuclear transport was altered. It is also 
possible that the increase in activity was due to post-translational modifications that were 
caused by ROS. Importantly, the increase in activity is likely due to changes in protein 
levels or post-translational modifications and not in cofactors, because an excess of 
cofactors is included in the TET activity assay, and cofactors such as -ketoglutarate are 
required for numerous other enzymes required for cell survival. Finally, the involvement 
of a TET1-mediated DNA demethylation mechanism was supported by the increase in 
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GFP expression in cells transfected with the cytidine deaminase AP2, further supporting 
an oxidation-deamination mechanism in DNA demethylation. 
 HQ exposure has long been known to increase ROS and affect the cell cycle, an 
effect attributed to disruption of microtubule assembly through sulfhydryl reactivity (18, 
21). Here we demonstrate that TET1 mediates the expression of 14-3-3 , a p53 target 
gene, in response to HQ exposure. Moreover, TET1 partially mediates the HQ-induced 
accumulation of cells in G2
  In summary, we have shown that a ROS-inducing chemical increases genome-
wide and gene-specific 5hmC formation through TET1 methylcytosine dioxygenase. 
Future studies should examine whether the observed effects are unique to HQ or shared 
by other xenobiotics that increase ROS. We suggest that TET1 represents a link between 
cellular redox status and maintenance of the epigenome.  
+M phases of the cell cycle, which could be due to its 
influence over 14-3-3 . It is possible that TET1 is involved in preventing cells from 
progressing through the cell cycle when ROS levels are elevated to protect the genome 
against damage and the accumulation of mutations that could promote uncontrolled cell 
growth. It is not clear whether TET proteins play a role in carcinogenesis or cell stress 
responses, although the role of TET1 in HQ-mediated expression of genes involved in 
cell cycle regulation and antioxidant defense warrants further study. Tumor tissues are 
reportedly low in 5hmC levels, and loss of TET expression has been demonstrated in 
malignant glioblastoma (36) and hepatocellular carcinoma samples (37), suggesting that 
loss of TET activity may contribute to tumorigenesis. To our knowledge, this is the first 
study to demonstrate that responses to ROS-mediated perturbations in the cell cycle are 




2.5  METHODS 
Chemicals and Reagents 
Unless otherwise stated, all chemicals and reagents were obtained from Sigma-Aldrich. 
Nit-GFP, human APOBEC2 (AP2), and TET1 catalytic domain plasmids were obtained 
from Dr. Hongjun Song’s laboratory (JHU) and used according the published methods 
(14). Silencer Select Predesigned siRNA against Tet1(4392420; ID s37194) and control 




HEK293 cells were obtained from ATCC and grown in DMEM supplemented with 10% 
FBS. Hydroquinone, menadione, buthionine sulfoximine, and N-acetylcysteine (NAC) 
stocks were freshly prepared in H2Oand sterile-filtered.  
 
 
Cell Viability MTT Assay 
Cytotoxicity was measured using standard 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) protocol. In brief, 1.5 x 104 cells were seeded in 
each well of a 96-well plate. Cells were exposed to the indicated concentrations of HQ 
for 24 h, washed with PBS, and incubated with 10 mg/ml MTT reagent in PBS at 37 °C 
for 1 h. Cells were lysed, and formazan crystals were dissolved in 100 µl of dimethyl 
43 
 
sulfoxide. Absorbance was read at 570 nm using a microplate reader, and data were 
expressed as a percentage of non-exposed cell MTT reduction. 
 
Western Blotting 
Whole cell lysates were prepared using radioimmunoprecipitation assay buffer and 
included addition of protease inhibitors. Protein concentrations were measured using the 
Bradford assay, and 30µg of whole cell lysates was separated on a 4–20% Tris-glycine 
gradient gel (Invitrogen). Nuclear lysates were prepared using Panomics Nuclear Extract 
kit (Fremont, CA) and measured using the Bradford assay. 15 µg of nuclear lysates was 
separated on a 4–12% Tris-glycine gradient gel (Invitrogen). Protein was transferred to a 
nitrocellulose membrane, blocked with 0.5% casein, and incubated overnight at 4 °C with 
antibodies against V5© (Invitrogen; 1:5000), FLAG-M2© (Sigma; 1:2000), actin 
(Sigma; 1:5000), TET1 (Abnova; 1:1000), or TATA-binding protein (Millipore; 1:1000). 
Blots were incubated with secondary antibody (1:10,000) for 1 h before visualization on 
the Licor Odyssey Imager. 
 
Quantitative RT-PCR 
RNA was isolated using TRIzol and quantified using NanoDrop. 1µg was used to 
generatecDNA (SuperscriptIII; Invitrogen). qPCR was performed using a Bio-Rad 
iCycler and iQ SYBR Green supermix according to the manufacturer’s instructions. 
Primers used were as follows:  
14-3-3  forward, GGCCATGGACATCAGCAAGAA 
14-3-3  reverse, CGAAAGTGGTCTTGGCCAGAG; 
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GAPDH forward, ACATCGCTCAGACACCATG 
GAPDH reverse, TGTAGTTGAGGTCAATGAAGGG; 
GCLCforward, AAAAGTCCGGTTGGTCCTG  
GCLC reverse, CCTGGTGTCCCTTCAATCATG; 
TET1 forward, TTCGTCACTGCCAACCTTAG 
TET1  reverse, ATGCCTCTTTCACTGGGTG; 
TET2 forward, CACTGCATGTTTGGACTTCTG  
TET2 reverse, TGCTCATCCTCAGGTTTTCC;  
TET3 forward, TCCGGATTGAGAAGGTCATC 
TET3 reverse, CCAGGCCAGGATCAAGATAA. 
 
 
Immunodotblotting of Genomic DNA 
Genomic DNA was isolated using GenElute Mammalian Genomic DNA kit (Sigma) and 
measured using a NanoDrop (Thermo Scientific). 250 ng was denatured with 0.4 M 
NaOH at 95 °C for 10 min. DNA was immobilized on nitrocellulose membrane using a 
96-well vacuum apparatus and then dried and fixed by vacuum baking at 80 °C. The 
membrane was then rehydrated in room temperature PBS and blocked with 0.5% casein 
for 1 hour prior to probing with antibodies against 8-hydroxy-2’-deoxyguanosine (8-oxo-
dG) (Trevigen; 1:2500), 5-mC (Active Motif; 1:1000), or 5-hmC (Active Motif; 1:8000). 
Mouse anti-single-stranded DNA (Abcam; 1:1500) antibody was used simultaneously for 
normalizing 5hmC. Antibody binding was measured using the Licor Odyssey. Methylene 
blue staining of DNA (0.04% with 0.3 M sodium acetate) was used for normalization of 
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8-oxo-dG and 5mC antibodies. Intensity of methylene blue was measured using ImageJ 
software (National Institutes of Health). Linear range of detection of DNA was 
determined by loading increasing amounts of single-stranded DNA and probing with 
increasing dilutions of anti-single-stranded DNA antibody. 5hmC Ab specificity was 
confirmed by blocking antibody with 2µg/ml 5hmC or 5mC at room temperature for 2 
hours and blotting DNA from mock-transfected and TET1-overexpressing HEK293 cells. 
 
 
Methylation-Sensitive Reporter Assay 
Nit-GFP plasmid was methylated using 4 units of CpG methyltransferase and 0.6mM S-
adenosylmethionine (New England Biolabs) at 30 °C for 12 hours and purified using 
Qiagen gel extraction columns. 2.5 x105
 
 HEK293 cells were transfected with 0.5 µg of 
methylated or unmethylated Nit-GFP plasmid, and co-transfections were used at 1:4 
GFP:TET1 (positive control), AP2, or gal for 48 hours using Lipofectamine. Cells were 
exposed to 60 µM HQ for 24 hours, beginning 24 hours after transfection. Cells were 
harvested using 0.25% trypsin-EDTA, fixed using ice-cold methanol:acetone (1:1), and 
stored at -20 °C. Cells were washed three times and resuspended in 4 °C PBS. GFP 
fluorescence was measured using a FACSCalibur flow cytometer (BD Biosciences) and 
analyzed using CellQuest software. Dead cell and doublet discrimination were 
accomplished using forward scatter versus side scatter gating, and at least 10,000 events 





Bisulfite sequencing was performed as reported by Guo et al. (14). At the end of the 24 
hour exposure to 60µM HQ, DNA from cells transfected with methylated Nit-GFP 
plasmid was isolated and bisulfite modified using the EpiTect bisulfite kit (Qiagen). The 
Nit-GFP promoter was PCR-amplified using primers recognizing the bisulfite-modified 
sequence and gel-purified. Bands of the predicted size were cloned into TOPO TA vector 
(Invitrogen) for sequencing (Johns Hopkins University DNA Analysis Facility). 6 CpGs 
within the promoter were read in 23 clones. Primers used for bisulfite-sequencing of Nit-




Measurement of Reactive Oxygen Species  
Cells were grown in opaque, black 96-well plates and incubated with 50µM (final 
concentration) 2’,7’-dichlorodihydrofluorescein diacetate (DCF-DA) in DMEM lacking 
phenol red for 30 min. DCF-DA was removed by washing twice with PBS, and cells 
were exposed to HQ, NAC (5 mM), or in combination. Fluorescence was measured at 
485em 522ex beginning at 30 min and followed through indicated time points. 
 
Immunoprecipitation of Hydroxymethylated/Methylated DNA  
Genomic DNA was isolated from cells exposed to hydroquinone or control conditions. 
8µg of DNA was sheared using intermittent sonication and validated to be 100–500 bp by 
gel electrophoresis. 2µg of DNA was heat-denatured for 10 min and placed immediately 
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in an ice bath. DNA was incubated with antibody against 5mC, 5hmC, or matched 
isotype control at 4 °C overnight. Protein G magnetic beads (Invitrogen) were added for 1 
hour at 4 °C with agitation, and bead-antibody-DNA complexes were magnetically 
separated, followed by three washes in immunoprecipitation buffer (4 °C PBS with 
0.05%Triton X-100). Protein was digested using proteinase K digestion buffer (50 mM 
Tris,pH8.0, 10mMEDTA) overnight at 50 °C. Proteinase K was inactivated by incubation 
at 80 °C for 30 min. DNA was purified using nucleic acid columns (Sigma). 
Immunoprecipitated DNA was used as a template for qPCR, and -fold enrichment was 
calculated using input DNA. Primers used for qPCR following 
hydroxymethylated/methylated DNA immunoprecipitation were as follows: 
LINE1 forward, TGCGGAGAAATAGGAACACTTTT 
LINE1 reverse, TGAGGAATCGCCACACTGACT (23);  
14-3-3  forward, CATTTAGGCAGTCTGATTCC 
14-3-3  reverse, GCTCACGCCTGTCATCTC (24);  
GCLC forward, CGTCCCAAGTCTCACAGTCA  
GCLC reverse, CTTTACGCAAACGCGACATA (25). 
 
 
Total Ten Eleven Translocation Activity Assay 
Total TET activity was measured using the Epigentek Epigenase5mChydroxylase kit 
(Farmingdale, NY) according to the supplier’s protocol. Nuclear lysates were prepared 
using Panomics Nuclear Extraction kit (Fremont, CA) and measured using the Bradford 
assay. Hydroxymethylated product formed was measured within a standard curve (0–2 
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ng), and activity was calculated as ng/min/mg. Data are expressed as -fold change over 
unexposed nuclear lysates. Overexpression of the TET1 catalytic domain was used as a 
positive control.  
 
DNA Content and Cell Cycle Analysis   
Cells were harvested using 0.25% trypsin-EDTA, followed by inactivation in DMEM 
containing 10% FBS. Cells were washed in cold PBS and then resuspended in 300 µl of 
PBS at 4 °C, and fixed overnight at -20 °C in 1:1 methanol:acetone, added dropwise with 
intermittent vortexing. Cells were washed with cold PBS and incubated with 0.25 ml of 5 
µg/ml RNase, 15 min at 37 °C. 0.25 ml of 100 µg/ml propidium iodide was added for 1 
hour at room temperature. DNA content was measured using a FACSCalibur flow 
cytometer and analyzed using Cell Quest software (BD Biosciences). Doublet 
discrimination was accomplished by gating on forward scatter-H v. FL3A and FL3A v. 
FL3-H. At least 10,000 events were analyzed in each sample, and each condition was 
replicated in triplicate.  
 
BrdU Labeling  
shEV and shTET1 HEK293 cells were pulsed with 10µM freshly prepared BrdU for 6 
hours at the end of a 24 hour exposure to 0- or 60µM HQ. Cells were harvested using 
0.25% trypsin-EDTA, followed by inactivation by 10% FBS-containing DMEM. Cells 
were washed twice with PBS and resuspended in 300µL PBS. Cells were fixed by adding 
ice-cold 70% ethanol drop wise with intermittent vortexing and stored overnight at -20˚C. 
Cells were washed with cold PBS, and resuspended in a 2mL solution of 0.4mg/mL 
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pepsin in 0.1M HCl, made fresh, for 30 minutes.  Cells were then washed in PBS, and 
resuspended in 300µL PBS. 1mL of 2M HCl was added drop wise with intermittent 
vortexing, followed by an additional 1mL of 2M HCl, and incubation at 37˚C. pH was 
neutralized by adding 12mL of 0.1M borax buffer, made fresh, for 10 minutes. Cells were 
pelleted and resusbpended in PBS with 0.05% Tween for permeablization. 
Approximately 1x106 
 
cells were aliquoted into 100µL and stained with 20µL anti-BrdU 
antibody for 1 hour at room temperature, followed by 1 hour incubation with secondary 
antibody in the dark. Cells were washed twice with PBS and resuspended in 1mL of PBS 
containing 10µg/mL propidium iodide. Cells were analyzed using a FACSCalibur flow 
cytometer and analyzed using Cell Quest software (BD Biosciences).  
Chromatin Immunoprecipitation (ChIP) 
Protein-DNA complexes were crosslinked using 37% formaldehyde, diluted to 1% final 
concentration in DMEM for 20 minutes at room temperature. Crosslinking was quenched 
by adding 1M glycine to 125mM final concentration for 10 minutes at room temperature. 
Cells were washed with PBS and pelleted. Cells were lysed using RIPA buffer with 
protease inhibitor cocktail (Sigma) and incubated on ice for 10 minutes. Lysates were 
sonicated for 10 cycles of 10 seconds on/10 seconds off on ice to produce chromatin 
approximately 500-1000bp. Chromatin size was validated using gel electrophoresis. Cell 
debris was removed by refrigerated centrifugation and supernatants were transferred to 
new tubes. DNA concentration was measured using nanodrop in input fraction saved 
from supernatants. Approximately 25µg DNA was used per immunoprecipitation, and 
1µg anti-FLAG or non-immune mouse IgG antibody was added overnight at 4˚C with 
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rocking. After incubation with antibody, 25µL magnetic protein G beads (Invitrogen) was 
added for 2 hours at 4˚C with rocking. Bead-antibody complexes were washed three 
times with RIPA containing protease inhibitors, and DNA was eluted by adding 100µL 
elution buffer containing 1% SDS and 100mM NaHCO3
14-3-3  forward, CATTTAGGCAGTCTGATTCC 
. DNA was purified using PCR 
purification kit (Sigma) and DNA was used as template for qPCR. Primers were as 
follows: 
14-3-3  reverse, GCTCACGCCTGTCATCTC (24);  
GCLC forward, CGTCCCAAGTCTCACAGTCA  




GraphPad Prism version 5 was used for statistical analyses. All data are summarized as 
mean ± S.E. Student’s t test was performed for all single analyses. Multiple comparisons 
were made using one-way analysis of variance (ANOVA) and Tukey’s, Dunnett’s, or 









III.   TET1 supports  H2AX formation and protection against DNA breaks in 
response to topoisomerase inhibition. 
 
3.1   ABSTRACT 
 Altered DNA methylation is a common trait observed in cancers, neurological 
diseases, and inflammatory syndromes. The frequent observation of altered epigenetic 
marks early in disease progression suggests they may play a causal role in the initiation 
of events leading to disease. Much effort has therefore been directed toward 
understanding regulation of DNA methylation in hopes of identifying targets for 
biomarkers and treatments. In general, cancer cells display genome-wide 
hypomethylation and promoter hypermethylation. It has been proposed that tumor cell 
DNA methyl transferases (DNMTs) have altered activities and binding sites, leading to 
inappropriate silencing of tumor suppressors. An additional regulator of gene expression 
may be Ten-Eleven Translocation (TET) 5-methylcytosine dioxygenases, which have 
been shown to lead to active DNA demethylation in mammalian cells. The role of TET1 
in changing the DNA methylation landscape and supporting the expression of 
cytoprotective genes such as GCLC and 14-3-3  raises the possibility that TET1 may be 
involved in preventing DNA damage that could result in tumor-promoting mutations. 
Consistent with this idea are the observations that hepatocellular carcinomas and 
malignant glioblastomas, among other cancer types, often display downregulated TET 
expression and 5hmC levels. It is unclear whether the altered TET system provides an 
advantage to tumor cells 
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 In this study, TET1 was knocked down using lentiviral vectors cells in HEK293 
to test its potential role in the response to the DNA double-strand break-inducing 
topoisomerase I inhibitor camptothecin (CPT). As expected, CPT exposure caused an 
increase in phosphorylated serine-139 of histone variant H2AX ( H2AX), G0+G1 
 While TET enzymes are primarily known for their role in gene expression by 
hydroxylating CpG methyl groups, this work demonstrates a novel non-enzymatic role 
for TET1. Moreover, a role for TET1 as a modifier of the response to DNA damage was 
arrest, 
and cell death. However, TET1-defiecient cells exposed to CPT accumulated 
significantly less H2AX and fewer cells stained positive for annexin V, suggesting that 
TET1-deficient decreases sensitivity to CPT. H2AX is induced by agent that cause 
DNA strand breaks and is often used to monitor DNA damage. H2AX is an earl step in 
the pathway in which DNA strand breaks are first recognized and then repaired. To 
determine whether differential levels of H2AX accumulation may indicate a role for 
TET1 in sensitivity to DNA damage or DNA repair, TUNEL labeling was used to 
measure exposed 3’OH ends in DNA. Interestingly, TET1-deficient cells exhibited 
significantly more DNA breaks in the presence or absence of CPT. These data suggest 
TET1 plays a role in the formation of H2AX and promotes cell death in response to 
DNA damaging agents. Confirming the role of TET1 in the formation of H2AX, 
overexpression of the catalytic domain of TET1 was able to rescue its induction in TET1-
deficient cells. Unexpectedly, catalytically-inactive mutant TET1 also rescued H2AX 
induction in response to CPT, indicating a non-enzymatic role for TET1 in response to 
DNA damage.  
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uncovered, which may form a foundation for future studies into the contribution of the 
pathway in disease.  
 
3.2   INTRODUCTION  
 Preservation of the genetic code is an essential cellular function, ensuring 
proliferation occurs in a regulated manner. Genetic material is persistently threatened by 
both endogenous and exogenous mutagens, such as reactive oxygen (ROS) and nitrogen 
(RNS) species and alkylating agents, which have great potential to alter the genetic code 
(1,2). Mutations in tumor suppressor genes have been shown to contribute to 
tumorigenesis and a multitude of neurological (3) and immunological diseases (4). For 
example, mutations in TP53, which have been observed in most tumor types, interfere 
with cell cycle regulation, attenuate DNA repair, and impair cells from undergoing 
programmed cell death following genotoxic insults. Experimental models of lung 
tumorigenesis in mice show that tobacco-derived carcinogens result in GA transitions 
at the second base of codon 12 and AT-GC transition or AT-TA transversions in codon 
61 in KRAS, an oncogene known to contribute to lung cancers in humans (54). Such 
mutations, if unchecked, may lead to uncontrolled cellular proliferation– an imbalance in 
mitosis and apoptosis – and malignancy.  
 While pre-cancerous cells accumulate mutations throughout the genome, gene 
promoters are more often methylated early in tumorigenesis. The tumor suppressors 14-3-
3 , p16 (INK4a), and p15 (INK4b) are often hypermethylated in their respective 
promoters in human cancers, and are thought to contribute to tumor formation by 
preventing cell cycle checkpoint regulation (55). GSTP1, a major phase II metabolism 
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enzyme known to facilitate clearance of reactive electrophiles, has been shown to be 
downregulated by promoter methylation in over 90% of prostate cancers (55). The 
MGMT gene, which repairs 06
 The DNA methylation landscape is established by DNA methyltransferases 
(DNMTs 1, 3a, 3b), which transfer a methyl group from S-adenosylmethionine to the 5-
carbon of cytosine. DNMT1, known as the maintenance methyltransferase, is thought to 
recognize hemi-methylated DNA during synthesis and transfer a methyl group to the 
daughter strand CpG. DNMT3a and DNMT3b are known as de novo methyltransferases, 
transferring methyl groups to both hemi- and unmethylated sites (39). Though the 
mechanisms involved in promoter-specific hypermethylation in cancer are poorly 
understood, it has been shown that oncogenic transcription factors can facilitate promoter 
methylation through their association with DNMTs. The PML-RAR fusion protein in 
acute promyelocytic leukemia is one of the first discoveries to illustrate this mechanism. 
Differential DNMT expression in various stages of the cell cycle in normal and cancer 
cells has also been suggested to contribute to the genomic hypomethylation observed in 
cancer cells (56).  
-alkyl-guanine, contributes to resistance to the alkylating 
agents Carmustine and Temozolomide in the treatment of malignant glioma. 
Interestingly, however, a significant survival benefit was observed in patients with 
methylated MGMT promoter and treated with alkylating therapeutic agents (56). Though 
still emerging, the roles of methylation-mediated gene silencing in disease are well-
accepted and discoveries are providing prognostic benefit. However, mechanisms of 
regulation over the complex DNA methylation dynamic are far from understood and 
present new challenges.  
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 An additional exciting area of investigation is the epigenetic regulation of genes 
in stem-like tumor propagating cells that likely contribute to recurrence following 
therapeutic intervention. Evidence has been published linking promoter methylation of 
genes involved in differentiation of stem and progenitor cells and activating histone 
modifications associated with promoters of transcription factors promoting stemness (57). 
These modifications in methylation will establish an epigenetic landscape promoting 
tumorigenic potential and therapeutic resistance in cell culture and xenografts studies of 
glioblastoma (57). Suva et al. described a network of four transcription factors capable of 
reprogramming more differentiated cells to stem-like cells, each of which are known to 
associate with the activating histone-3 acetylation (H3K27ac) mark. DNA methylation 
and histone modifications are functionally linked, and efforts to target enzymes involved 
in either pathway may have far reaching effects throughout the genome. For example, the 
methyl-DNA binding protein MeCP2 is known to bind histone deacetylase (HDAC), 
coupling CpG methylation to the removal of activating histone marks. Targeting DNA 
methylation, therefore, has the ability to affect larger scale chromatin architecture and the 
expression of numerous genes located far from the methylation site. Clinical trials of 
drugs shown to cause demethylation, such as Decitabine and Zebularine, are currently 
being investigated and have shown clinical benefit (45).  A significant goal in designing 
novel therapies is defining the epigenetic circuitry allowing for reprogramming in hopes 
of targeting the pools of stem-like cells in the bulk tumor (57).  
  Recent work has shown that TET 5-methylcytosine dioxygenases, -
ketoglutarate- and divalent iron-dependent enzymes that hydroxylate methyl groups 
added by DNMTs, lead to stable 5hmC or initiate a multistep process of active 
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demethylation (7). In light of the significant role of TET proteins’ contribution to active 
demethylation, the DNA methylome is being appreciated as more dynamic than 
previously thought. The idea that TET-mediated 5hmC is a stable base is an intriguing 
one. High levels of 5hmC in human and mouse brain and embryonic stem cells support 
this notion, though there is also evidence to suggest neuronal activity cooperates with 
TET1 to demethylate CpGs and activate transcription of activity-regulated genes (7). 
TET activity is therefore thought to influence gene expression in multiple ways. First, if 
5hmC is indeed a stable “sixth base,” then the base is predicted to change the binding 
affinity of methyl-binding domain-containing proteins, such as MBD2 and MeCP2, 
which are known to participate in blocking transcription factor binding as well as 
orchestrating chromatin architecture changes which repress gene expression (39). 
Secondly, the presence of 5hmC in a promoter may affect the ability of DNMT1 to 
recognize the position as methylated, thus leading to a demethylated daughter strand (51). 
Third, TET activity that results in demethylation of cytosine would essentially erase the 
restrictive methyl mark, relieving the repression brought about by the mark itself or its 
numerous binding proteins. It has also been proposed that some transcription factors may 
bind to 5hmC-containing promoters with increased affinity (51).  
 It has been demonstrated that numerous cancers have decreased TET expression 
and activity, and the global content of 5hmC is nearly uniformly low compared to non-
tumor tissue (36,37). Increased methylation of CpGs by DNMTs along with the lack of 
TET activity in tumor cells – either by loss of TET expression or through 
oncometabolite-induced inhibition of activity - is thought to contribute to the so-called 
CpG Island Methylator Phenotype (CIMP) of cancers (39). It is tempting to think that 
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downregulation of TET enzymes provides advantages to tumor cells by shifting the 
methylation dynamic toward a hypermethylation phenotype. For example, could the lack 
of TET-promoted cytoprotective genes lead to increased genomic instability or resistance 
to DNA damaging agents? Could low TET enzyme levels or activity lead to silencing of 
pro-apoptotic genes that would otherwise be active in a non-tumor cell? Are low levels 
and activities of TET enzymes merely supportive of tumorigenesis or required? The 
consequences of low TET expression and 5hmC levels are not well understood, and 
provide a potentially rich area for exploration into mechanisms of tumor initiation and 
therapeutic resistance.   
 In this study, evidence suggesting that TET1 plays a role in the response to DNA 
damage is presented. TET1 was stably knocked down in HEK293 cells using lentiviral 
vectors to evaluate the effects of the topoisomerase I inhibitor camptothecin (CPT). The 
inhibitor is a prototypical inducer of DNA double strand breaks resulting in activation of 
the  p53 pathway and apoptosis. Control cells displayed phosphorylation of histone 
variant H2A.X at serine-139 ( H2AX), accumulation of cells in G0+G1, and decreased 
viability following exposure to CPT. TET1-deficient cells treated with CPT accumulated 
significantly less H2AX and fewer cells stained positive with annexin V, indicating 
lower sensitivity to the drug. In order to determine whether differential levels of H2AX 
represented resistance to CPT-induced damage or a deficient response to damage, 
TUNEL labeling was conducted to quantify cells with damaged DNA. Interestingly, 
TET-1 knockdown led to a significant increase in damaged DNA both with and without 
CPT exposure compared to control cells. While TET1 is known to support the expression 
of cytoprotective genes in the context of stress, both active and inactive TET1 catalytic 
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domain overexpression surprisingly rescued H2AX formation in TET1 knockdown cells 
exposed to CPT, indicating a non-enzymatic role for the protein in response to DNA 
damage.  
 These data are the first to indicate a non-enzymatic role for TET1 in the response 
to a DNA damaging agent, and suggest that TET1 plays a significant function in 






3.3   RESULTS 
TET1 Supports H2AX Formation Following Exposure to Camptothecin in HEK293 
Cells 
 As expected, a 14 hour treatment of 1µM camptothecin (CPT) led to an increase 
in formation of serine-139 phosphorylation of histone variant H2A.X on ( H2AX) in 
HEK293 cells (Fig. 1A). However, the amount of H2AX was lower in TET1-deficient 
cells treated with CPT (Fig. 1B and C). The effects of CPT were dose-dependent though 
the differences between cell lines were observed at each dose (Fig. 1D). 
Immunofluorescent staining was used to confirm that the differential levels of H2AX 
formed as characteristic foci in cells exposed to CPT and not a diffuse increase 




Figure 1: TET1 knockdown decreases formation of H2AX following camptothecin 
exposure.  A, Tet1 mRNA levels measured by qRT-PCR in HEK293 cells following 
infection with lentivirus encoding shRNA against Tet1(shTET1) or empty pLKO vector 
(shEV). GAPDH levels are used as control. B, Western blot of H2AX in shEV and 
shTET1 cells following 1µM CPT exposure for 14 hours. GAPDH is used as loading 
control, and ratios are represented in C. D, Western blot of H2AX in shEV and shTET1 
cells following 0-, 1-, 3-, or 10µM CPT for 14 hours. GAPDH levels are used as control. 
E, Representative immunofluorescent images of H2AX (red) in shEV and shTET1 cells 
following 14 hours of 0-, 1,  or 3µM CPT. DAPI (blue) represents heterochromatin. 








































Camptothecin-Induced H2AX Formation is Dependent on TET1 Catalytic Domain, 
but Independent of Catalytic Activity 
 To confirm the dependence of H2AX on TET1 and test the requirement for 
TET1 activity on H2AX formation in response to CPT exposure, shEV and shTET1 
cells were exposed to 3µM CPT for 14 hours 24 hours following transfection of gal, 
catalytically active mouse FLAG-tagged TET1 (Tet1-CD), or mouse mutant catalytically 
inactive FLAG-tagged TET1cd (Tet1-CDmut). Both Tet1-CD and Tet1-CDmut 
overexpression were able to rescue formation of H2AX following exposure to CPT, 
suggesting that CPT-induced H2AX is not associated with hydroxylation of 5mC by 
TET1 (Fig 2A and B).  Immunodotblotting confirmed that the highly conserved mouse 
TET1 catalytic domain increased 5hmC similarly to human TET1 catalytic domain 
cloned from HEK293 cells. An increase of 5hmC in HEK293 cells transfected with 
catalytically active mouse Tet1-CD, but not catalytically inactive mouse Tet1-CDmut 













Figure 2: Activity-independent rescue of camptothecin-induced H2AX by TET1. A, 
Western blot of H2AX in shEV and shTET1 cells following 0- or 3µM CPT exposure 
for 14 hours following transfection with gal, FLAG-tagged Tet1-CD, or FLAG-tagged 
Tet1-CDmut. GAPDH was used as loading control, and ratios of H2AX / GAPDH are 
shown in B. C, Immunodotblot of 5hmC in untransfected HEK293 cells or 





















TET1-deficiency Leads to Dampened H2AX Levels Independent of ATM or p53 
Activation 
  The ability of TET1 overexpression to rescue H2AX levels following CPT 
treatment raises the possibility that TET1-deficient cells are less vulnerable to damage or 
have altered activation of ATM, a kinase known to phosphorylate H2AX in response to 
DNA damage. Western blotting of phospho-ATM (pATM), and phospho-p53 (pSer15-
p53) show that control and TET1-deficient cells had similar levels of activated ATM and 
p53 following CPT treatment (fig. 3). These data suggest CPT leads to DNA damage and 
activation of sensors of damage in TET1-deficient cells, and that differential H2AX 














Figure 3: TET1 influence over H2AX is independent of ATM or p53 activation.  
Representative western blots of whole cell lysates from shEV and shTET1 cells showing 
phosphorylated ATM (pATM), TET1, p53 serine-15 phosphorylation (pSer15-p53), and 






















TET1 Is protective Against DNA Breaks in HEK293 Cells 
 While H2AX formation is often interpreted as an indicator of DNA damage, the 
phosphorylated histone also plays an integral role in the recognition of DNA damage and 
the coordination of complexes of proteins involved in repair. To determine whether 
TET1-supported H2AX formation leads to protection against DNA breaks, Terminal 
deoxynucleotide transferase dUTP Nick End Labeling (TUNEL) labeling of free 3’OH 
ends was carried out in shEV and shTET1 cells following CPT treatment. Interestingly, 
an increase in the number of TUNEL+ cells was observed in TET1-deficient cells with 
and without CPT exposure (Fig. 4A-C). While a greater number of shTET1 cells 
displayed  (average = 60.85%) breaks compared to shEV cells (average = 22.8%) at 24 
hours after treatment with CPT, a greater number of shTET1 cells displayed breaks 
(greater than 2-fold compared to shEV) in the absence of CPT. While the TUNEL+ 
population in untreated shTET1 cells was less than 1% of the gated cells, the observation 











Figure 4: TET1 is protective against DNA breaks in vitro. A, Representative dot plots of 
DNA breaks measured by flow cytometry in shEV and shTET1 cells exposed to 0- or 
3µM CPT for 24 hours. Exposed 3’OH ends were labeled with brominated-dUTP, stained 
with FITC-conjugated anti-BrdU antibody, and counterstained with propidium iodide to 
visualize DNA content. The x-axis represents relative DNA content and the y-axis 
represents log-scale relative BrdU labeling. TUNEL+ cells are quantified and represented 
in B and C. At least 10,000 events were collected in technical triplicates and the 


















TET1 Supports Cell Death Following Exposure to Camptothecin in HEK293 Cells 
 TET1 knockdown led to an increase in the number of cells labeled by TUNEL 
staining. However, the TUNEL assay does not necessarily correlate with apoptosis
 Nor does it distinguish apoptotic cells from necrotic cells, or cells with breaks as 
a result of chemical or physical insult. To determine the potential contribution of 
TET1 to cell death, shEV and shTET1 cells were exposed to 0-, 3-, or 10µM CPT for 24 
hours and stained with annexin V, which binds to phosphatidyl serine either 
extracellularly, indicating apoptosis, or intracellularly, suggesting loss of membrane 
integrity (Fig. 5A-B). An increase in annexin V staining of 1.6 and 2-fold was observed in 
shEV cells exposed to 3- and 10µM CPT, respectively. Differences were not observed in 
apoptosis between shTET1 cells and control cells without treatment, suggesting 
that TET1 promotes or permits cell death to occur in response to CPT.  
 While the catalytic domain of TET1, but not TET1 activity, was involved in  
H2AX formation and protection against DNA damage, the requirement for TET1 
protein and activity in CPT-mediated cell death was tested by overexpressing TET1-CD 
and TET1-CDmut and staining for annexin V. Catalytically active TET1-CD was able to 
enhance annexin V labeling in shEV cells and rescue sensitivity to CPT at both 3- and 
10µM in shTET1 cells (Fig. 5D). Catalytically inactive TET1-CDmut was able to rescue 
sensitivity to CPT at 10µM (Fig. 5E), suggesting that TET1 catalytic domain, but not 





Figure 5: Non-enzymatic promotion of cell death by TET1 catalytic domain.  A, 
Representative histograms of annexin V fluorescence in shEV (blue) and shTET1 (red) 
cells exposed to 0-, 3-, or 10µM CPT for 24 hours. At least 10,000 events were collected 
in each sample, and results from 3 experiments are shown in B. Annexin V staining of 
shEV and shTET1 cells exposed to 0-, 3-, or 10µM CPT for 24 hours following 




















TET1 Knock Down Increases Sphere-forming Capacity of Glioblastoma Tumor 
Initiating Cells 
 Because TET1 knockdown led to characteristic features of cancer cells - an 
increase in DNA damage and decreased sensitivity to the DNA damaging agent 
camptothecin – the ability of TET1 knockdown to affect the growth of glioblastoma 
(GBM) sphere-forming cells was tested. 20913 GBM cells were maintained as non-
adherent spheres in culture with defined medium containing EGF and FGF growth factors 
and passaged by breaking into single cells. Lentiviral-mediated shRNA against TET1 was 
used to generate a stable TET1 knockdown in GBM cells (Fig. 6A) and the ability of the 
cells to form spheres was assayed after 5 days.  shTET1-20913 GBM cells generated 
more spheres compared to shEV-20913 cells ( 50 µM or 100µM) , and the spheres 
were larger ( 100µM) (Fig 6B and C). mRNA of KLF4, Sox2, Nanog, and Pax6, genes 
involved in maintaining stemness of GBM cells were found to be higher in shTET1-
20913 cells, though the differences were slight and not likely biologically significant 
(data not shown). However, POU5f1 (Oct4) mRNA was found to be upregulated > 2-fold 
following TET1 knockdown (Fig. 6D). Oct4 has been shown to be a critical factor 
involved in reprogramming of both induced-pluripotent (iPS) cells and glioblastoma cells 
to a stem-like state. Additionally, NeuroD1, a transcription factor promoting neuronal 
differentiation was found to be downregulated following TET1 knockdown.  
 Noting the increase in sphere-forming capacity of GBM cells following TET1 
knockdown, the Rembrandt database containing gene expression and survival data from 
human brain tumors was used to probe for a potential association between TET1 
expression and survival in glioma (Fig 6E). A positive association between TET1 
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expression and survival was observed in patients with tumors containing up-regulated 
TET1 (n=29) versus intermediate expressed TET1 (n=302) (Log-rank p-value: 0.0099). 
The association was also observed in patients with tumors containing up-regulated TET1 
versus down-regulated TET1 (n=12) (Log-rank p-value: 3.53x10-6
  
), and intermediate 
expressed TET1 versus down-regulated TET1 (Log-rank p-value: 0.006).  
Figure 6: Knockdown of TET1 in human glioblastoma tumor-initiating cells enhances 
sphere forming capacity. A, Sphere-formation assay showing numbers of shEV or 
shTET1 GBM-20913 spheres 50 µM (A) or 100µM (B) formed 5 days after 
dissociation into single cells. C, Representative image of spheres in agar following 5 days 
growth in suspension. D, Oct4 and NeuroD1 mRNA in shEV and shTET1 GBM -20913 
cells measured by qRT-PCR. E, Kaplan-Meier curves indicating glioma patient survival 
following stratifying tumors into up-regulated (n=29), intermediate (n=302), or down-






























































3.4   DISCUSSION 
  Here we present evidence that TET1 is involved in the formation of •H2AX and 
protects against DNA damage in response to topoisomerase 1 inhibition. We further 
demonstrate that the catalytic domain, but not activity, is necessary to support •H2AX 
formation, decrease DNA breaks, and promote cell death in response to camptothecin. 
This result was unexpected, as TET1 expression has been shown primarily to support 
gene expression through demethylation. For example, active demethylation by TET1 was 
shown to be functionally involved and necessary in activity-induced FGF and BDNF 
expression in mouse brain. Additionally, the hydroquinone-induced expression of 
cytoprotective genes GCLC and 14-3-3  were TET1-dependent and were shown to be 
demethylated in a mechanism involved 5hmC. TET1 knock down rendered cells 
susceptible to a significant increase in DNA breaks, yet relatively resistant to cell death. 
These seemingly paradoxical outcomes could lead to aneuploidy or accumulation of 
mutations and translocations. Interestingly the increase in DNA breaks was observed in 
TET1-deficient cells even in the absence of an exogenous stressor, suggesting that TET1 
plays a role in maintaining routine repair and apoptosis in the face of endogenous and 
random genomic insults.  
 Noting that decreasing levels of TET1 in HEK293 cells led to an increase in DNA 
breaks and resistance to cell death induced by CPT, we sought to determine the effect of 
knocking down TET1 in human glioblastoma cells known for aggressiveness and stem-
like qualities. We found that knocking down TET1 in glioblastoma sphere-forming cells 
led to an increase in both the number and size of spheres formed, and that TET1-deficient 
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cells had higher mRNA levels of the pluripotency-related transcription factor Oct4, 
suggesting that TET1 levels seem to be linked to stemness of glioblastoma cells.  
 Interest in TET proteins has increased dramatically with the discovery that they 
contributed to active demethylation. Claims of bona fide demethylase enzymes in 
mammals have not been verified and, until the discovery of TET enzymes, passive 
demethylation via inhibition of DNMTs was the only known mechanism of DNA 
demethylation. The biology of TET proteins is also potentially important in cancer 
biology, as their downregulation has been observed in numerous cancers. For example, 
Orr et al. studied 5hmC marks in 225 human gliomas and found that genomic levels were 
lower in high grade tumors and low levels of 5hmC were negatively correlated with 
survival in glioblastoma. Additionally, Liu et al. reported 5hmC levels in hepatocellular 
carcinoma (HCC). Low 5hmC correlated with tumor size and poor prognosis, and TET1-
3 genes were downregulated in HCC. These studies are provocative and suggest that 
downregulation of TET expression or activity may provide advantages to tumor cells. 
Our study demonstrates that TET1 plays a role in the formation of H2AX, an important 
signal of DNA damage, as well as protection against DNA breaks and the promotion of 
cell death following DNA damage. While the loss of TET1 in our model led to 
characteristic features of cancer cells – increased DNA breaks and decreased cell death in 
response to DNA damage – it remains to be seen whether the loss of TET proteins or 
activity play a significant role in tumorigenesis or cancer biology. 
 It is unclear why formation of H2AX in response to CPT is blunted in TET1-
deficient cells. Kinases known to phosphorylate H2AX could be involved, though we 
show that there is no difference in activated (phosphorylated) ATM levels, a major player 
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in H2AX phosphorylation in response to CPT. It is possible that the catalytic domain of 
TET1 interacts with a kinase, recruiting it to close proximity to damaged sites to 
phosphorylate H2AX. In this way, loss of TET1 could lead to loss of H2AX without a 
loss of phosphorylation of other ATM targets, such as p53. Consistent with this idea is 
the fact that our studies show no difference in phospho-ATM or serine-15 
phosphorylation of p53, a known target of ATM. An additional possibility is that TET1 
affects ATM activity through its binding partner O-linked N-acetylglucosamine 
transferase (OGT). TET1 has been shown to interact with OGT, which catalyzes 
serine/threonine glycosylation of numerous proteins. A major function of OGT is to 
regulate enzyme activity by competing with kinases for serines and threonines on target 
proteins. Interestingly, ATM is known to be activated by OGT-mediated glycosylation. 
Future studies should test the ability of TET1 to directly or indirectly regulate ATM 
activity. A third possibility is that binding partners of the catalytic domain of TET1 bring 
about global changes in chromatin architecture, opening chromatin to allow kinases and 
repair proteins to access sites of DNA damage. Studies have reported that 
heterochromatic regions are refractory to phosphorylation of H2AX, though the 
mechanisms are not well-understood.  
 In summary, we highlight a novel, non-enzymatic role for TET1 in the response 
to DNA damage by CPT. We demonstrate that the catalytic domain of TET1 is sufficient 
to rescue H2AX formation, and that TET1 protects against endogenous and exogenous 
DNA damage, suggesting it may be involved in diseases involving altered DNA repair 
and apoptosis. We also show that decreasing levels of TET1 in stem-like glioblastoma 
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cells increased sphere-forming capacity, which is consistent with the idea that TET1 






3.5   METHODS 
Cells and Lentivirus Production 
HEK293 cells were obtained from ATCC and grown in DMEM supplemented with 10% 
FBS. pLKO shRNA vectors targeting TET1 (Thermo Scientific) or the empty vector 
were co-transfected with Pax2 and MDG2 plasmids for packaging and envelop 
production, respectively, at a ratio of 1:3:2 into HEK293FT cells. Lipofectamine was 
used for transfections at 30µL/10mL in 10cm dishes. DMEM medium was replaced after 
an overnight incubation with transfection reagents. 48 hours following transfection, the 
medium was collected and centrifuged. Supernatant was collected and filtered using 
22µm filter cap. HEK293 target cells were seeded at low density in 6 well plates and 
incubated for 30 minutes with  5µg/mL polybrene. Supernatant containing lentiviral 
paricles was applied to HEK293 cells overnight. Following 24 hours incubation, infection 
medium was removed and DMEM containing 10% FBS and 1µg/mL puromycin was 
applied to select transduced cells. Puromycin concentration was determined as the lowest 
dose capable of killing untransfected HEK293 cells. Cells with integrated pLKO 
encoding empty vector (shEV) or shRNA against TET1 (shTET1) were cultured in the 
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presence of puromycin until plated for an experiment. 20913 Glioblastoma sphere-
forming cells were maintained in defined medium supplemented with EGF and FGF 
growth factors. Transduction with lentiviral particles encoding empty vector or shRNA 
against TET1 was accomplished as noted for HEK293 cells, yet virus was harvested in 
DMEM medium lacking FBS. 
 
 
Western Blotting and Antibodies 
Whole cell lysates were prepared using radioimmunoprecipitation assay buffer and 
included addition of protease inhibitors. Protein concentrations were measured using the 
Bradford assay, and 30µg of whole cell lysates was separated on a 4–20% Tris-glycine 
gradient gel (Invitrogen). Protein was transferred to a nitrocellulose membrane, blocked 
with 0.5% casein, and incubated overnight at 4 °C with antibodies against pATM (Cell 
Signaling, 1:1000), TET1 (Abnova, 1:1000), pSer15-p53 and total p53 (Cell Signaling, 
1:1000), GAPDH (Sigma, 1:5000), FLAG M2 (Sigma, 1:1000), or H2AX (Abcam, 
1:1000). Blots were incubated with secondary antibody (1:10,000) for 1 h before 




HEK293 cells were grown on glass coverslips and allowed to adhere overnight.Cells 
were exposed to camptothecin or DMSO control for 14 hours and fixed in 3.7% 
formaldehyde for 20 minutes. Following 3 washes in cold PBS, cells were stored at 4˚C 
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in PBS until staining. Cells were permeablized and blocked in PBS with 0.2% TritonX-
100 and 2.5% BSA for 2 hours at room temperature. Cells were incubated in PBS with 
2.5% BSA and rabbit anti- H2AX antibody (1:200) overnight at 4˚C. Following 
incubation with primary antibody, cells were washed for 5 minutes three times in PBS at 
room temperature. Cells were incubated with Texas Red anti-rabbit secondary antibody 
for 2 hours at room temperature, followed by 3 washes in PBS. Cells were mounted and 
coverslipped using ProLong Gold antifade reagent with DAPI (Life Technologies) and 




Immunodotblotting of Genomic DNA 
Genomic DNA was isolated using GenElute Mammalian Genomic DNA kit (Sigma) and 
measured using a NanoDrop (Thermo Scientific). 250 ng was denatured with 0.4 M 
NaOH at 95 °C for 10 min. DNA was immobilized on nitrocellulose membrane using a 
96-well vacuum apparatus and then dried and fixed by vacuum baking at 80 °C. The 
membrane was then rehydrated in room temperature PBS and blocked with 0.5% casein 
for 1 hour prior to probing with antibodies against 5-hmC (Active Motif; 1:8000). Mouse 
anti-single-stranded DNA (Abcam; 1:1500) antibody was used simultaneously for 
normalizing 5hmC. Blots were then washed in PBS three times and then incubated with 
IR-cojugated secondary antibodies (Ms 600, Rb 800). Binding was measured using the 





Cloning of Human TET1 Catalytic Domain 
mRNA was prepared from HEK293 cells using Trizol and cDNA was prepared using 
Superscript III Reverse Transcriptase (Life Technologies). The catalytic domain of TET1 
was amplified with Taq DNA polymerase and pfu Taq High Fidelity Taq polymerase 




Reverse:   
ATACCGGGTACC.TCATCAGACCCAATGGTTATAGGG 
PCR product was run on a 1% agarose gel to confirm expected size of 2700bp and 
restriction digested with EcoR1 and Kpn1 prior to insertion into pcDNA3.1(-) 
mammalian expression vector under control of CMV promoter. Plasmids were sequenced 
to validate correct orientation and sequence of the insert (JHU DNA Analysis Facility). 




TUNEL Assay for Flow Cytometry 
HEK293 shEV and shTET1 cells were exposed to indicated concentrations of 
camptothecin for 24 hours. Cells were trypsinized and harvested along with any non-
adherent cells and washed with cold PBS. Labeling was accomplished according to 
Phoenix Flow Systems (San Diego, CA) recommended protocol. In brief, to ensure 
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smaller DNA fragments were included, cells were resuspended in 1% (w/v) 
paraformaldehyde in PBS at 1x106 cells/mL for 60 minutes. Cells were then washed in 
PBS and resuspended in 70% ethanol overnight. Following washes, 1x105 cells were 
labeled in 100µL of  solution containing provided buffer, terminal deoxynucleotidyl 
transferase enzyme, BrdU, and distilled H2
 
O in a 37˚C water bath for 4 hours. Cells were 
agitated every 20 minutes throughout the labeling incubation. Following the reaction, 
cells were washed and then labeled with FITC-conjugated anti-BrdU antibody for 30 
minutes, then diluted with propidium iodide/RNase A solution to label DNA. Cells were 
analyzed using a FACSCalibur flow cytometer and analyzed using Cell Quest software 
(BD Biosciences).Single-cells were gated using FL3A v. FL3W and the R3 gate 
consisted of positively labeled cells in FL1, set by included negative and positive control 
cells provided by the manufacturer.  
 
Annexin V Labeling for Cell Viability 
HEK293 shEV and shTET1 cells were exposed to indicated concentrations of 
camptothecin for 24 hours and washed in cold PBS. Cells were resuspended in binding 
buffer:  10mM HEPES, 140mM NaCl, and 2.5 mM CaCl2, pH 7.4 at 1x105
 
cells/100µL. 
5µL 488-conjugated annexin V in the dark for 15 minutes. After the incubation, 400µL 
binding buffer was added and cells were kept on ice until analysis using a FACSCalibur 




Sphere Formation Assay 
Cells were incubated in neurosphere culture medium 5 days and embedded in low-
melting agar. Spheres were stained overnight at 4˚C in Wright's solution (1%) and de-
stained in PBS. Sphere formation was analyzed by computer-assisted morphometry 
(MCID) by measuring the number of neurospheres 50 µM or 100µM in diameter in 





IV.   CONCLUSIONS, PERSPECTIVES, AND FUTURE STUDIES 
 
4.1   Toxicant-induced DNA demethylation of cytoprotective genes through 
increased TET1 activity. 
 Environmental exposures have been known to affect DNA methylation. Bollati et 
al., for example, studied methylation levels of specific genes in participants with variable 
exposures to benzene (9). 78 gas station attendants, 77 traffic officers, and 58 
“unexposed” control participants were included in the study. For every 10-fold increase 
in airborne benzene levels, the authors observed significant decreases in methylation of 
LINE-1 and Alu1, suggesting a genome-wide decrease. In addition, hypomethylation of 
MAGE-1 and hypermethylation of p15 were also observed. Studies in TK6 
lymphoblastoid cells also show that numerous compounds, including benzene and 
hydroquinone, lead to widespread demethylation of DNA. While associations between 
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environmental and pharmaceutical chemicals and DNA methylation have been widely 
known, mechanistic data, which could be used to develop biomarkers and predict effects 
of chemically similar compounds, were not available. 
 In chapter 2, we investigated the ability of the major benzene metabolite, 
hydroquinone, to change DNA methylation using an in vitro model system. We found 
that hydroquinone exposures that did not affect viability, but which did affect gene 
expression, led to decreases in genomic DNA methylation in a mechanism involving 
ROS. We further demonstrated the involvement of the 5-methylcytosine dioxygenase 
TET1 in the active demethylation of LINE-1, GCLC, and 14-3-3 , implicating TET1 in a 
functional response to ROS. The proposed mechanism involves no single demethylase, 
but a multi-step process of demethylation involving hydroxylation of the methyl group, 
followed by deamination to form 5-hydroxymethyluracil (5hmU). Base excision repair 
(BER) would be expected to replace 5hmU with cytosine. Indeed, Guo et al. 
demonstrated an accumulation of 5hmU with TET1 overexpression and small molecule 
inhibitors of BER (7). When we overexpressed the human deaminase AP2, we observed 
an enhanced demethylation in cells exposed to hydroquinone, suggesting that the 
chemical leads to demethylation through the same or a similar pathway. Finally, we were 
able to link TET1 to changes in the cell cycle following hydroquinone exposure, which 
have been reported as early as 1953. It is possible that chemical exposures affecting G2 to 
M progression, like hydroquinone, may involve TET1, and cells lacking TET1 continue 
to cycle, leaving them vulnerable to mutations. While TET1 is clearly affected by 
hydroquinone and a similar compound, menadione, it is unclear how ROS affects TET1 
protein levels and activity (58). TET1 contributed to most of the 5mC hydroxylase 
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activity in HEK293 cells, but it is not know whether chemicals affect the other TET 
members. 
 While each of the three TET proteins catalyzes the same reaction, their temporal 
and tissue-specific distributions vary greatly. While TET3 is highly expressed in germ 
cells, TET1 is highly expressed in the brain, lung, heart, and liver and TET2 is expressed 
in bone marrow, lymphocytes, brain, and spleen. It is remarkable how little is known 
about their regulation, both at the transcriptional and activity levels. For example, TET1 
and TET3 contain a CXXC-domain toward the amino terminus which is very similar to 
DNMT1. In DNMT1, the domain is known to bind DNA with high affinity, yet the 
domain binds DNA with very little affinity in TET1 and TET3. In fact, the CXXC 
domain is dispensable for enzymatic activity in vivo. Our data, in agreement 
with numerous other studies, show that overexpression of the human or mouse catalytic 
domain is sufficient to cause global increases in 5hmC. Interestingly, the amino terminus 
of TET2 underwent an inversion during evolution and is now transcribed as a separate 
gene, IDAX2, leaving TET2 as a shorter gene with no CXXC domain (51). IDAX  is 
shown to bind DNA and recruit TET2 to DNA, where it is then targeted for caspase 
cleavage. It is not yet known whether TET1 or TET3 are regulated in a similar manner, or 
if the amino terminus plays any important role in its activity or destruction. The carboxy 
terminus contains a cysteine-rich region close to the catalytic site, though a function of 
the region is not known. Tahiliani et al,. in a landmark publication describing the 
function of TET1, demonstrated that the protein had a tendency to form dimers when run 
on a non-denaturing, non-reducing gel, presumably due to disulfide bond formation at the 
cysteine-rich regions (12). A possibility could be that perturbations in redox status from a 
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reducing environment to a localized region of ROS in the nucleus affects the cysteine-
rich regions of TET1, leading to retention of the protein in the nucleus.  
 Future studies need to be conducted to determine whether DNA demethylation 
involving TET1 is unique to hydroquinone or common to chemicals that cause ROS. Our 
observation of increased 5hmC following exposure to menadione suggests that the effect 
is not unique to hydroquinone, and a recent publication reported that numerous quinone 
compounds were able to decrease DNA methylation in a TET1-dependent manner.  
 While benzene is a ubiquitous environmental chemical, there are specific 
populations exposed to significantly higher exposures, such as those living in urban 
environments and workers exposed to high concentrations of hydrocarbon fuels and 
combustion. It should be noted, however, that airborne benzene, while impossible to 
eliminate, can be monitored and regulated. Benzene is also a component of one fracturing 
fluid (gel) that has been used in hydraulic fracturing, and the mixture of compounds that 
are liberated following hydraulic fracturing are complex mixtures potentially containing 
benzene. The effects of environmental chemicals on the human epigenome should 
continue to be studied in order to better characterize risks to health. In addition, it may be 
possible to develop biomarkers of exposures and risks if we can determine genetic 
“hotspots” likely to change in methylation. 
   
Preliminary Study into Alzheimer’s Disease and Global 5hmC  
 Noting that hydroquinone caused a ROS-dependent increase in 5hmC (58), we 
were curious to know whether a disease that may involve ROS (59), environmental 
toxicants, and changes in DNA methylation may show changes in global 5hmC as well 
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(49,50). We obtained 5 post-mortem samples each of Hippocampus, Broadmann Area 22 
(BA22), and Broadmann Area 46 (BA46) from patients who had varying stages of 
Alzheimer’s disease (AD) (60). Using immunodotblotting, we measured the global levels 
of 5hmC and found 5hmC levels in the hippocampus (Fig. 1A)  increased from Braak 
Stages 1 and 2 (least severe and associated aging) to Stages 3 and 4, and further still to 
Stages 5 and 6 (most severe). 5hmC levels decreased from Stages 1 and 2 to all other 
stages in Broadmann Area 22 (Fig. 1B), and were unchanged in Broadmann Area 46 (Fig. 
1C).  
 While preliminary, our data show that changes in 5hmC increase with severity of 
Alzheimer’s disease in hippocampus. The involvement of ROS in the disease is well-
accepted and future studies should involve identifying differences in specific gene 
methylation that occur in AD as well as potential biomarkers that could be measured in 
blood or sputum. A prospective study with regularly sampled blood or sputum collection 
could provide a rich data set that could be used to develop methylation marks that are 












Figure 1:  Global 5hmC increases with severity of AD in hippocampus. 
Immunodotblotting was used to measure global 5hmC levels in hippocampus (A), 
Broadmann Area 22 (B), and Broadmann Area 46 (C). 5hmC was normalized to ssDNA. 
Samples were measured in triplicate and immunodotblotting was replicated twice.           











































Diagnosis Age Sex PMI 
Braak 1 65 M 18.57 
Braak 1 59 M 18.43 
Braak 1 72 M 24.87 
Braak 2 72 M 6.83 
Braak 2 74 M 25 
average 68.4  18.74 
Braak 3 87 F 22.32 
Braak3 86 F 10.6 
Braak 4 90 M 24 
Braak 4 77 F 27.07 
Braak 4 72 M 23.72 
Average 82.4  21.542 
Braak 5 82 M 16.92 
Braak 5 82 F 17.18 
Braak 6 86 F 27.83 
Braak 6 82 F 12.16 
Braak 6 82 F 21.5 




4.2   Activity-independent protection against DNA damage by TET1.  
 DNA methylation and the molecular components establishing, erasing, and 
interpreting the marks are crucial elements in cellular functions. Highlighting their 
importance are the growing lists of diseases and disorders involving changes in DNA 
methylation. Alzheimer’s disease (global increases and decreases in both 5mC and 
5hmC), cancers (low global 5mC, high promoter 5mC, low 5hmC), and Lupus (decreased 
promoter 5mC), for example, each have significant epigenetic components and contribute 
greatly to worldwide morbidity and mortality. While aberrant DNA methylation has been 
described and linked to gene expression in many diseases, the overarching mechanisms 
leading to changes are not well-understood, and represent potential targets for biomarkers 
and intervention. Moreover, defects in the molecular machinery involved in establishing 
and interpreting epigenetic marks also lead to profound disease and disability. For 
example, Rett Syndrome, caused by mutations in the gene encoding the 5mC-binding 
MeCP2 protein, is a debilitating neurodevelopmental disorder characterized by loss of 
purposeful hand movements and severe cognitive defects. Rett Syndrome can be cause by 
mutations throughout the gene, however, and not all mutations in MeCP2 disrupt binding 
to 5mC, indicating additional important roles for the protein. 
 In Chapter 3 we report a non-enzymatic role for TET1 in responding to DNA 
damage induced by the topoisomerase inhibitor CPT. Loss of TET1 rendered cells more 
sensitive to DNA breaks, yet relatively resistant to cell death. Re-introducing the catalytic 
domain of the conserved mouse TET1 protein rescued the formation of H2AX, an 
important recognition signal of DNA damage, in response to CPT. While transient 
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overexpression of human or mouse TET1 catalytic domain led to fold-increases in global 
5hmC, catalytically inactive mouse TET1 was sufficient to rescue H2AX formation and 
sensitize cells to CPT. The lack of enzymatic activity required to rescue TET1-deficient 
cells suggests a novel role for the protein, perhaps involving novel binding partners. We 
also report that knocking down TET1 in glioblastoma sphere-forming cells led to an 
increase in both number and size of spheres, further implicating the protein as a relevant 
player in cancer biology.   
 Future studies should be directed toward understanding regulation of TET1 in 
different contexts. For example, despite a lack of change in TET1 mRNA, we observed a 
significant increase in its activity when exposed to hydroquinone. The protein could be 
translocated from the cytoplasm to the nucleus, cleaved by proteases, or inhibited from 
being translated by microRNA’s in certain environments or cell types. Recent interest in 
microRNA-mediated regulation of genes has surged, and these non-protein coding RNAs 
may serve cancer cells by inhibiting TET1-mediated protection, thereby providing 
chemo- and radio-resistance. A better understanding of the regulation of TET1 is critical 
in providing a mechanistic explanation of diseases involving epigenetic changes. It is our 









Figure 2:  Proposed novel roles for TET1 in response to stress. Stresses such as 
ROS lead to increased TET1 activity, resulting in the efficient expression of genes 
involved in cell cycle regulation and antioxidant defense. TET1 promotes 
phosphorylation of histone variant H2AX in an activity-independent manner, 
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